Posters - 21/11/24

Doi : 10.14283/jpad.2018.40

Le texte complet de cet article est disponible en PDF.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Le texte complet de cet article est disponible en PDF.

Plan

Theme: Clinical Trials Methodology

P21: Patterns of Mmse Subtest Scores in Amyloid-Positive and -Negative Participants In J-Adni. Ryoko Ihara¹, Kazushi Suzuki¹, Atsushi Iwata², Takeshi Iwatsubo^1,3, the Japanese Alzheimer's Disease Neuroimaging Initiative ((1) The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo -Japan; (2) Department of Neurology, The University of Tokyo, Tokyo -Japan; (3) Department of Neuropathology, The University of Tokyo, Tokyo – Japan)

P45: Innovations in Care Community-Based Recruitment to Clinical Trial Research. Jacobo Mintzer¹, Mike Splaine², Erin Beck³ ((1) Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; Managing Partner, Recruitment Partners LLC, Columbia, MD, USA; (2) Managing Partner, Recruitment Partners LLC, Columbia, MD, USA; (3) Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA)

P54: Validation Of Alzheimer'S Biomarkers: Β-Amyloid 1–42 and Total Tau in Csf By Automated Cleia on Lumipulse G 1200 Platform. Satya Nandana Narla¹, Amanda Dider¹, Ming Hu¹, Tina LV², Yuan Xueling², Martine Florent¹ ((1) Immunology Department, Covance Central Laboratories, Indianapolis, USA; (2) Immunology Department, Covance Central Laboratories, Shanghai, China)

P59: The Impact of Frailty on the Risk of Screen Failure in Randomized Controlled Trials on Alzheimer'S Disease. Alessandro Trebbastoni, Marco Canevelli, Giuseppe Bruno, Carlo de Lena, Letizia Imbriano, Fabrizia D'Antonio, Laura Pieroni (Department of Human Neuroscience, «Sapienza» University of Rome, Italy)

P61: Concierge Site Services: Site-Specific Support and Capacity Development Improves Recruitment Performance. Jacobo Mintzer¹, Mike Splaine², Erin Beck³ ((1) Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; Managing Partner, Recruitment Partners LLC, Columbia, MD, USA; (2) Managing Partner, Recruitment Partners LLC, Columbia, MD, USA; (3) Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA)

P82: Meotis3Rc : Efficient Network for Clinical Research on Cognitive Disorders In North And Pas-De Calais. Catherine Adnet-Bonte¹, Brigitte Leprince¹, Laetitia Breuilh^2,3, Florence Pasquier^2,3 ((1) Meotis, Centre Hospitalier Universitaire de Lille, France; (2) Neurology Department, Centre Hospitalier Universitaire de Lille, France; (3) Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille)

P86: Recruiting Older Latinos in Senior Centers with a Culturally Tailored Alzheimer'S Presentation. Jaime Perales¹, W Todd Moore¹, Mariana Ramírez¹, Linda Lara², Erica Davis³, Jason Resendez⁴, Eric D Vidoni¹ ((1) University of Kansas Medical Center, Kansas-USA; (2) Guadalupe Center, Kansas City-USA; (3) Don Bosco Senior Center, Kansas City-USA; (4) LatinosAgainstAlzheimer's Coalition, Chevy Chase-USA)

P90: REVERSE-SD: ONGOING PHASE-2B STUDY OF NEFLAMAPIMOD DESIGNED IN ACCORDANCE WITH EMERGING SCIENTIFIC AND REGULATORY CONCEPTS OF EARLY ALZHEIMER'S DISEASE (AD). John Alam¹, Kelly Blackburn¹, Niels Prins^2,3, Philip Scheltens² ((1) EIP Pharma Inc., Cambridge, MA, USA; (2) Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL; (3) Brain Research Center, Amsterdam, NL)

P91: A Phase 2B/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of Anavex®2-73 For The Treatment of Early Alzheimer'S Disease Together with Precision Medicine Genetic Biomarkers. Stephen Macfarlane¹, Michael Kornhauser¹, Ella Modini¹, Harald Hampel², Stephan Toutain³, Christopher Missling³ ((1) HammondCare Dementia Centre, NSW -Australia; (2) Sorbonne University, Paris -France; (3) Anavex Life Sciences Corp., New York -USA)

P92: Aimpact of Genetic Testing on Clinical Trial Participation and Subject Selection, a Pilot Study. Marieke Cajal-Berman¹, Jessica Branning², Vishnukartik Nitta² ((1) Bioclinica Research, Orlando, FL, USA; (2) ClinCloud, Orlando, FL, USA)

P93: The Impact of Transcranial Magnetic Stimulation on Diagnostic Confidence in Patients With Alzheimer Disease Eligible for Clinical Trials. Alberto Benussi^1*, Antonella Alberici^1*, Clarissa Ferrari^2*, Valentina Cantoni^1,3, Valentina Dell'Era¹, Rosanna Turrone¹, Maria Sofia Cotelli⁴, Giuliano Binetti², Barbara Paghera⁵, Giacomo Koch^6,7, Barbara Borroni¹, Alessandro Padovani¹ ((1) Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; (2) IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (3) Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy; (4) Neurology Unit, Ospedale Vallecamonica, Esine, Brescia, Italy; (5) Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy; (6) Non Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Rome, Italy; (7) Stroke Unit, Policlinico Tor Vergata, Rome, Italy; *These authors contributed equally to this work)

P94: Applying Patient-Centred Insights to Optimize Protocol Design and Increase Biomarker Collection Acceptability in Ad Trials. Kenneth Stanley, Carolina Rubel, Lynne Hughes (IQVIA Project Leadership Unit)

P95: Csf Biomarkers Outcomes in the Etheral Ad Study. Harald Hampel^1,2,3,4, Carlos Buesa⁵, Tamara Maes⁵, Mabel Arevalo⁵, Michele Lufino⁵, Roger Bullock⁵(1) AXA Research Fund & Sorbonne University Chair, Paris, France; (2) Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; (3) Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225Paris, France; (4) Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; (5) Oryzon Genomics SA, Barcelona, Spain)

P96: Emif-Ad: A Unique Pan-European Platform for Large-Scale Research On Biomarkers and Risk Factors For Alzheimer'S Disease. Preciosa M Coloma¹, Stephanie J. B. Vos², Isabelle Bos², Andy Simmons³, Rik Vandenberghe⁴, Philip Scheltens⁵, José Luis Molinuevo^6,7, Flavio Nobili⁸, Sebastiaan Engelborghs^9,10, Giovanni Frisoni^11,12, Gaël Chetelat¹³, Alberto Lleó¹⁴, Anders Wallin¹⁵, Julius Popp^16,17, Pablo Martinez-Lage¹⁸, Gonzalo Duran-Pacheco¹, Pieter Jelle Visser^2,5, Mark F Gordon¹⁹, Gerald Novak²⁰ ((1) Personalised Health Care -Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland; (2) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands; (3) Institute of Psychiatry, Kings College, London, UK; (4) University Hospital Leuven, Leuven, Belgium; (5) Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; (6) Alzheimer's disease & other cognitive disorders unit, Hopsital Clínic-IDIBAPS, Barcelona, Spain; (7) Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain; (8) Clinical Neurology, Department of Neurosciences (DINOGMI), University of Genoa and IRCCS Polyclinic San Martino Hospital, Genoa, Italy; (9) Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium; (10) Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; (11) University of Geneva, Geneva, Switzerland; (12) IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (13) Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France; (14) Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; (15) University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden; (16) Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland; (17) Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland; (18) CITA-Alzheimer Foundation, San Sebastian, Spain; (19) Teva Pharmaceuticals, Malvern, PA, USA; (20) Janssen Pharmaceutical Research and Development, Titusville, NJ, USA)

P97: Using Transcription Phenotypes to Utilise Basket Trial Methodology from Oncology to Create New Targets in Cns Disorders. Roger Bullock¹, David Rotllant¹, Michele Lufino¹, Cristina Mascaro1 Carlos Buesa¹, Tamara Maes¹, Sonia Gutierrez¹, Marta Valverde², Tony Ramos² ((1) Oryzon Genomics, Barcelona, Spain; (2) Vall D'Hebron Hospital, Barcelona, Spain)

P98: Can Online Registers with Small Amounts of Phenotypic Data Reduce Screen Failure Rates in Alzheimer'S Disease Trials? Piers Kotting¹, Kris Beicher², Adam Smith³, Clare Shaw² ((1) University of Exeter Medical School, Exeter, UK; (2) University of Leeds, Leeds, UK; (3) Institute of Neurology, University College London, London, UK)

P99: Trial Design of the Graduate Studies: Phase Iii, Randomized, Placebo-Controlled Studies Evaluating Gantenerumab in Patients With Early Alzheimer'S Disease. Smiljana Ristic¹, Mercè Boada², Nathalie Pross¹, Danielle Abi-Saab¹, Szofia Bullain¹, Mirjana Andjelkovic¹, Paul Delmar¹, Carsten Hofmann¹, Alison Searle³, Monika Baudler¹, Paulo Fontoura¹, Rachelle Doody⁴ ((1) F. Hoffmann-La Roche Ltd., Basel, Switzerland; (2) Barcelona Alzheimer Treatment and Research Center, Barcelona, Spain; (3) Roche Products Ltd., Welwyn Garden City, UK; (4) Genentech, Inc., South San Francisco, CA, USA)

P100: Study Enrollment and Alzheimer'S Disease Pathology in Relation to Cohort Type And Participant Characteristics in the Epad Registry. Lisa Vermunt¹, Graciela Muniz-Terrera^2,3,4, Lea ter Meulen¹, Colin Veal⁵, José Luis Molinuevo⁶, Pierre-Jean Ousset^7,8, Niels D Prins^1,9, David Porteous², Craig W Ritchie², Philip Scheltens¹, Gerald Luscan¹⁰, Anthony J Brookes⁵, Pieter Jelle Visser^1,11 ((1) VU University Medical Center, Amsterdam – Netherlands; (2) University of Edinburgh, Edinburgh – Scotland; (3) University of Victoria, Victoria – Canada; (4) University of Cambridge, Cambridge – England; (5) University of Leicester, Leicester – England; (6) Barcelona Beta Research Center, Barcelona – Spain; (7) Clinic University Hospital, Barcelona – Spain; (8) CHU Toulouse, Gérontopôle and INSERM UMR 1027, Toulouse – France; (9) Brain Research Center, Amsterdam – Netherlands; (10) Pfizer, Paris – France; (11) Maastricht University, Maastricht – Netherlands)

P101: The Effects of Participant Characteristics and Selection Criteria on Alzheimer Disease Clinical Trial Outcomes. Richard E. Kennedy¹, Guoqiao Wang², Mackenzie E. Fowler³, Gary R. Cutter⁴, Lon S. Schneider⁵ ((1) Department of Medicine, University of Alabama at Birmingham, USA; (2) Division of Biostatistics, Washington University, St. Louis, USA; (3) Department of Epidemiology, University of Alabama at Birmingham, USA; (4) Department of Biostatistics, University of Alabama at Birmingham, USA; (5) Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA)

Theme: Clinical trials: Results

P7: Effects of Vortioxetine on Cognitive Functions in Patients With Alzheimer'S Disease and Depressive Symptoms: Interim Results of an Observational Study. Eduardo Cumbo, Silvia Cumbo, Salvatore Torregrossa, Daniela Migliore (Neurodegenerative Disorders Unit, ASP 2 Caltanissetta, Caltanissetta (Italy)

P12: Critical Path for Alzheimer'S Disease (Cpad) Consortium'S Vision For An Aggregated, Standardized, And Actionable Global Alzheimer Disease Clinical Trial Database. Volker D. Kern¹, Stephen P. Arneric¹, Maria C. Carrillo², James Hendrix², Billy Dunn³, Stacie Weninger⁴, Jeffrey A. Kaye⁵, Daniel R. Karlin⁶, Lisa H. Gold⁷, Michael Gold⁸, Samantha Budd Haeberlein⁹, Molly Shea¹⁰, George Vradenburg¹¹, Daniela J. Conrado¹, Klaus Romero¹ ((1) Critical Path for Alzheimer's Disease Consortium, Critical Path Institute, Tucson, AZ, USA; (2) Alzheimer's Association, Chicago, IL, USA; (3) U.S. Food and Drug Administration, Silver Spring, MD, USA (4) F-Prime Biomedical Research Initiative, Cambridge, MA, USA; (5) Oregon Health & Science University, Portland, OR, USA; (6) Pfizer, Boston, MA, USA; (7) Merck & Co., Inc., Kenilworth, NJ, USA; (8) AbbVie, North Chicago, IL, USA; (9) Biogen, Cambridge, MA, USA; (10) Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; (11) UsAgainstAlzheimer's, Washington, DC, USA)

P13: Effects of Body Weight on Safety of 23Mg Donepezil In Alzheimer'S Disease: A Post-Hoc Analysis of a Multicenter, Randomized Trial. Yun Jeong Hong^1,2, Hyun Jeong Han³, Young Chul Youn⁴, Kyung Won Park⁵, Dong Won Yang⁶, Sang Yun Kim⁷, Hwa Jung Kim⁸, Ji Eun Kim⁹, Jae-Hong Lee,¹, the ODESA study group ((1) Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; (2) Biomedical research institute, Pusan National University Hospital, Pusan; (3) Neurology, Dementia and Neurocognitive Center, Myongji Hospital, Seonam University College of Medicine, Ilsan; (4) Neurology, Chung-Ang University Hospital, Seoul; (5) Neurology, Dong-A University College of Medicine, Busan; (6) Neurology, The Catholic University of Korea, Seoul; (7) Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam; (8) Preventive Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul; (9) Neurology, University of Ulsan College of Medicine, Gangneung Asan Medical Center, Gangneung, Korea)

P15: A Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Ly3303560, A Tau-Specific Antibody, In Healthy Volunteers. Stephen Lowe¹, Jeffrey Dage², Ann Cleverley³, Albert Lo², Elizabeth S. LaBell², Hakop Gevorkyan⁴, Stanford Jhee⁵, Larry Huffman², Boris Calderon², Brian A. Willis² ((1) Lilly Centre for Clinical Pharmacology, Singapore; (2) Eli Lilly and Co, Indianapolis, IN; (3) Eli Lilly and Co, Erl Wood, UK; (4) California Clinical Trials Medical Group, Inc.; (5) PAREXEL Early Phase, Glendale, CA, USA)

P16: Cnp520, A Novel Oral Bace1 Inhibitor, Has No Clinically Meaningful Effect on Qtc Interval Up to Supratherapeutic Doses. Stefan Viktor Vormfelde¹, Nicole Pezous¹, Gilbert Lefèvre¹, Carine Kolly¹, Ulf Neumann1, Pierre Jordaan², Guenter Heimann², Mike Ufer¹, Ana Graf², Eric Legangneux¹ ((1) Novartis Institutes for BioMedical Research, Basel, Switzerland; (2) Novartis Pharma AG, Basel, Switzerland)

P18: Differences in Treatment Response Between Males and Females with Mild-Moderate Alzheimer Disease Being Treated with Cholinesterase Inhibitors. Kenneth Rockwood^1,2, Justin Stanley¹, Susan E Howlett^1,2,3 ((1) DGI Clinical Inc., Halifax, NS, Canada; (2) Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada; (3) Department of Pharmacology, Dalhousie University, Halifax, NS, Canada)

P36: Phase 1 Clinical Studies in Alzheimer'S Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of Amyloid Β Aggregate-Specific Antibody Khk6640. Marc Cantillon, MD¹, Hiroyuki Shimada², Kenichiro Sugiyama³, Wei Sun¹, Yoshiumi Ouchi³, Katsuyoshi Tsukii¹, Gemma Clark⁴ ((1) Kyowa Kirin Pharmaceutical Development, Inc., USA; (2) Osaka city university hospital, Osaka, Japan; (3) Kyowa Hakko Kirin Co., Ltd., Japan; (4) Kyowa Kirin International plc, UK)

P80: Cumulative Aducanumab Safety Data from Prime: A Randomized, Double-Blind, Placebocontrolled, Phase 1B Study. Philipp von Rosenstiel¹, Tianle Chen¹, John O'Gorman¹, Min Yee¹, Carmen Castrillo-Viguera¹, Claudia Prada¹, Christoph Hock², Roger M Nitsch², Samantha Budd Haeberlein¹, Alfred Sandrock¹ ((1) Biogen, Cambridge, MA, USA; (2) Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland)

P109: The Action for Health in Diabetes Clinical Trial: Does A 10-Year Intensive Multidomain Lifestyle Intervention Provide Cognitive Benefits? Kathleen M. Hayden¹, José A. Luchsinger², Stephen R. Rapp¹, Delilah R. Cook¹, Rebecca H. Neiberg¹, Judy L. Bahnson¹, Tara D. Beckner¹, Jerry M. Barnes¹, Mark A. Espeland¹, for the Look AHEAD MIND Study Group ((1) Wake Forest School of Medicine, Winston-Salem, USA; (2) Columbia University, New York, USA)

P110: Single And Multiple Dose Safety, Tolerability and Pharmacokinetics of the Selective M1 Receptor Partial Agonist Htl0018318 in Healthy Volunteers. Tim Tasker¹, Jan Liptrot¹, Charlotte Bakker², Ellen' t Hart², Erica Klaassen², Samantha Prins², Thalia van der Doef², Mike Walker², Giles A. Brown¹, Alastair Brown¹, Miles Congreve¹, Malcolm Weir¹, Fiona H. Marshall¹, David M. Cross⁴, Geert Jan Groeneveld², Pradeep. J. Nathan^1,3 ((1) Sosei Heptares, Cambridge UK; (2) Centre for Human Drug Research (CDHR), Leiden, Netherlands; (3) Department of Psychiatry, University of Cambridge, UK; (4) Cross Pharma Consulting Limited, Cambridge, UK)

P111: Assessing the Psychological and Emotional Impact Of Apoe And Amyloid Disclosure in the Api Generation Program: Interim Findings. Jessica B. Langbaum¹, Jason Karlawish², Scott Roberts³, Angela Bradbury², Scott Kim⁴, Elisabeth McCarty Wood², Carolyn Langlois¹, Fonda Liu⁵, Marie-Emmanuelle⁶, Marie-Laure Rouzade-Dominguez⁶, Angelika Caputo⁶, Mauritz Bezuidenhoudt⁶, Cristina Lopez-Lopez⁶, Ana Graf⁶, Pierre N. Tariot¹, Eric M. Reiman¹ ((1) Banner Alzheimer's Institute, Phoenix, USA; (2) University of Pennsylvania, Philadelphia, USA; (3) University of Michigan, Ann Arbor, USA; (4) National Institutes of Health, Bethesda, USA; (5) Novartis Pharmaceuticals Corporation, East Hanover, USA; (6 ) Novartis Pharma AG, Basel – Switzerland)

P112: META-ANALYSIS OF TWO TAU AGGREGATION INHIBITOR PHASE 3 TRIALS IN MILD ALZHEIMER'S DISEASE WITH LOW DOSE HYDROMETHYLTHIONINE. Bjoern Schelter^1,2, Claude Wischik^1,2 ((1) Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK; (2) TauRx Therapeutics, Aberdeen, UK)

Theme: Clinical trials: Imaging

P10: Diagnostic Accuracy of [18F]Fc119S Pet for Identifying Alzheimer'S Disease. Byung Hyun Byun, Sang Moo Lim (Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, -Republic of Korea)

P35: Annual Atrophy Rate in Normal Aging from a Large Single-Center Cohort in Korea. Yu Yong Choi¹, Byeong C. Kim², Seong-Min Choi², Kee Hyung Park³, Kyu Yeong Choi¹, Kun Ho Lee^1,4 ((1) National Research Center for Dementia, Chosun University, Gwangju, South Korea; (2) Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea; (3) Department of Neurology, Gachon University College of Medicine, Incheon, South Korea; (4) Department of Biomedical Science, Chosun University, Gwangju, South Korea)

P62: Impact of Cerebral Blood Flow Changes on 18F-Florbetaben Suvr. A Simulation Study. Santiago Bullich¹, Norman Koglin¹, Susan De Santi², Georg A. Becker³, Audrey Perroti¹, Aleksandar Jovalekic¹, Andrew Stephens¹, Henryk Barthel³, Osama Sabri³ ((1) Piramal Imaging GmbH, Berlin, Germany; (2) Piramal Pharma Inc., Boston, MA, USA; (3) Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany)

P76: F-Av-1451 in Tdp-43 Associated Frontotemporal Dementia. Ruben Smith¹, Alexander F Santillo¹, Maria Landqvist Waldö², Oskar Hansson^1,3 ((1) Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden; (2) Memory Clinic, Ängelholm Hospital, Ängelholm, Sweden; (3) Memory Clinic, Skåne University Hospital, Malmö, Sweden)

P113: Predicting Amyloid Burden from Cognitive Assessment. Donald R. Royall^1–4, Raymond F. Palmer³ for the Alzheimer's Disease Neuroimaging Initiative* ((1) Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA; (2) Department of Medicine, UTHSCSA, San Antonio, Texas, USA; (3) Department of Family & Community Medicine. UTHSCSA, San Antonio, Texas, USA; (4) South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA)

P114: The Triple Use Of Amyloid Pet in Alzheimer'S Disease. Federica Ribaldi^1,2, Moira Marizzoni¹, Valentina Garibotto³, Michela Pievani¹, Giovanni B Frisoni^1,3 ((1) IRCCS Fatebenefratelli, Brescia -Italy; (2) University of Brescia, Brescia – Italy 3 Geneva University Hospitals, Geneva -Switzerland)

P115: A Comparison of Cortical Reporter Regions for Longitudinal Analysis Of 18Fav1451 Pet Data. David Scott₁, Katarzyna Adamczuk¹, Beth Gorman², Maureen Runkle², Joyce Suhy¹ and the Alzheimer's Disease Neuroimaging Initiative ((1) Bioclinica, Newark, CA, USA; (2) Bioclinica, Philadelphia, PA, USA)

P116: Can Tau Pet Imaging Be Instrumental in Predicting an Elevated Amyloid Level in Clinical Trials. Sergey Shcherbinin¹, Michael J. Pontecorvo², Ming Lu², Michael D. Devous Sr², A. Joshi², Sudeepti Southekal², Emily C. Collins^1,2, Adam S. Fleisher², Mark A. Mintun^1,2 ((1) Eli Lilly & Co, Indianapolis, IN, USA; (2) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA)

P117: Supratentorial White Matter is a Better Reference for Longitudinal Quantification of [18F]Flutemetamol Scans. Gemma Salvadó¹, Chris Foley², Elisabetta Grecchi^2,3, M. Jorge Cardoso^4,5, Isadora Lopes-Alves⁶, Pawel Markiewicz⁵, Carles Falcon¹, Mark Battle², Adriaan A. Lammertsma⁶, Mark Schmidt⁷, José Luis Molinuevo¹, Frederik Barkhof^5,6, Juan Domingo Gispert¹ ((1) Barcelonaβeta Brain Research Center, Barcelona, Spain; (2) GE Healthcare, Amersham, United Kingdom; (3) IXICO, London, United Kingdom; (4) King's College London, London, United Kingdom; (5) University College London, London, United Kingdom; (6) VU Medical Center, Amsterdam, The Netherlands; (7) Janssen Pharmaceutica, Beerse, Belgium)

P118: Clinical Validation of 18F-Pi-2620 for Quantification of Tau In Subjects With Alzheimer'S Disease. Andrew Stephens¹, Andre Mueller¹, Santiago Bullich¹, Mathias Berndt¹, John Seibyl², Olivier Barret², Jennifer Madonia², Heiko Kroth³, Andrea Pfeifer³ Andreas Muhs³, Gilles Tamagnan², Kenneth Marek², Ludger Dinkelborg¹ ((1) Piramal Imaging, Berlin, Germany; (2) Invicro, New Haven, USA; (3) AC Immune SA, Lausanne, Switzerland)

P119: Cut-Off for 18F-Flutemetamol Suvr with White Matter Reference Region. Katarzyna Adamczuk¹, David Scott¹, Ben Newton³, Joyce Suhy¹, Michael Egan², Cyrille Sur² ((1) Bioclinica, Newark, CA, USA; (2) Merck Sharp & Dohme, Kenilworth, NJ, USA; (3) General Electric Health Care, Amersham, UK)

P120: Amyloid Pet Imaging in a Phase Iia, Randomized, Double-Blind, Placebocontrolled, 3-Arm Parallel-Group, Multicenter Study With Ub-311. Hui Jing Yu¹, Hui-Chen Chen¹, Jacob Hesterman², Jack Heimann², Sean Holmes², Alex Whittington², Xue Wang², Roger Gunn², Ajay Verma¹ ((1) United Neuroscience, Inc. Hauppauge, NY, USA; (2) Invicro, A Konica Minolta Company, Boston, MA, USA)

P121: Cortical Dopamine Depletion and Cognition in Lewy Bodies Disorders: A 123I-Fpcit Single-Subject Study. Andrea Pilotto^1,2, Francesca Schiano di Cola¹, Enrico Premi¹, Roberto Grasso¹, Rosanna Turrone¹, Stefano Gipponi¹, Andrea Scalvini¹, Elisabetta Cottini¹, Barbara Paghera³, Laura Bonanni⁴, Maria Cristina Rizzetti², Barbara Borroni¹, Alessandro Padovani¹ ((1) Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; (2)Parkinson's Disease Rehabilitation Centre, FERB ONLUS S.Isidoro Hospital, Trescore Balneario (BG), Italy; (3) Nuclear Medicine Unit, University of Brescia, Brescia, Italy; (4) Department of Neuroscience Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy)

P122: Very Early Detection and Treatment Monitoring of Alzheimer'S Disease in the Retina By Multimode, Hyperspectral Confocal Scanning Ophthalmoscopy. Daniel L. Farkas^1,2, Fartash Vasefi¹, Jeanne M. Fontana¹ ((1) The Brain Window, Inc., Sherman Oaks CA, USA; (2) University of Southern California, Los Angeles CA, USA)

P123: Quantitative Analysis on the Goodness of Harmonization With Multivariate Analysis Of Field Strength, Sex, Age And Total Intracranial Volume. Mirza Faisal Beg¹, Da Ma1, Karteek Popori¹, Mahadev², Lei Wang³ ((1) School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada; (2) Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; (3) Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA)

P124: Prescribing Cholinesterase Inhibitors in Mild Cognitive Impairment – Observations from the Alzheimer'S Disease Neuroimaging Initiative. Eddie Stage¹, Diana Svaldi¹, Sophie Sokolow^2,5,6, Shannon L. Risacher¹, Krisztina Marosi², Kwangsik Nho¹, Jerome I Rotter^3,4, Andrew J. Saykin¹, Liana G. Apostolova¹ ((1) Indiana Alzheimer Disease Center, Indianapolis, IN, USA; (2) UCLA School of Nursing, Los Angeles, CA, USA; (3) Division of Genomic Outcomes, Department of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA; (4) Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA; (5) UCLA Brain Research Institute, Los Angeles, CA, USA; (6) UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA)

Theme: Clinical trials: Biomarkers and including plasma

P1: Sustained Attention and Memory Tasks with Concurrent Eeg Provide Potential Biomarkers for Mild Cognitive Impairment. Shani Waninger¹, Chris Berka¹, Amir Meghdadi¹, David Salat², Ajay Verma³ ((1) Advanced Brain Monitoring, Inc., Carlsbad, CA; (2) MGH/MIT/HMS) Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA; (3) United Neuroscience, Dublin, Ireland)

P4: High Correlation in the Aβ40 And Aβ42 Levels in Human Cerebrospinal Fluid as Measured By Elisa and Hplc-Ms/Ms. José A. Allué, Leticia Sarasa, Virginia Pérez-Grijalba, Noelia Fandos, Pedro Pesini, Manuel Sarasa (Araclon Biotech S.L., Vía Hispanidad 21, 50.009, Zaragoza, Spain)

P22: Cerebrospinal Fluid Biomarkers in J-Adni: Diagnostic Accuracy in Ad and Predictability Of Future Clinical Change in Mci. Kazushi Suzuki¹, Ryoko Ihara¹, Atsushi Iwata¹, Takeshi Iwatsubo1, Kenji Ishii², Takeshi Ikeuchi³, Ryozo Kuwano³ Japanese Alzheimer's Disease Neuroimaging Initiative ((1) The University of Tokyo, Tokyo, Japan; (2) Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; (3) Niigata University, Niigata, Japan)

P28: Analytical Performance of the Lumipulse® G Ptau 181 and Lumipulse® G Β-Amyloid 1–40 Assays. Manu Vandijck, Martine Dauwe, Rosina Degrieck, Els Huyck, Nathalie Le Bastard, Geert Jannes, Vesna Kostanjevecki (Fujirebio Europe NV, Ghent, Belgium)

P30: Curcumin is Detectable in Human C E R E B R O S P I Nal Flui D Af T Er Oral Administration Of Turmeric Extract Hsrx-888. Norman Relkin¹, Dan Li², Joshua Costin², David Wyatt³ ((1) Relkin Consulting LLC, Harrington Park, NJ 07640; (2) HerbalScience Group, Naples FL, USA; (3) Syneos Health, Miami FL, USA)

P39: Diagnostic Biomarkers' Clinical Applicability in Early Onset Alzheimer'S Disease. Neus Falgàs¹, Raquel Sánchez-Valle¹, Mircea Balasa^1,2, Sergi Borrego¹, Magdalena Castellví¹, Adrià Tort-Merino¹, Jaume Olives¹, Beatriz Bosch1, Guadalupe Fernández¹, Franscisco Lomeña³, Núria Bargalló⁴, Albert Lladó1 ((1) Alzheimer's disease and other cognitive disorders Unit. IDIBAPS. Hospital Clínic de Barcelona; (2) Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland; (3) Nuclear Medicine Department. IDIBAPS. Hospital Clínic de Barcelona; (4) Image Diagnostic Centre. IDIBAPS. Hospital Clínic de Barcelona)

P44: Inverse Association Between Aβ42/40 Plasma Ratios and Fibrillary Amyloid Deposition in the Brain: Results of the Facehbi Study. Itziar de Rojas¹, Judith Romero², Octavio Rodríguez-Gomez¹, Pedro Pesini², Angela Sanabria¹, Alba Pérez-Cordon¹, Carla Abdelnour¹, Isabel Hernández¹, Maitee Rosende-Roca¹, Ana Mauleón¹, Liliana Vargas¹, Montserrat Alegret¹, Ana Espinosa¹, Gemma Ortega¹, Silvia Gil¹, Marina Guitart¹, Anna Gailhajane¹, Miguel Angel Santos-Santos¹, Sonia Moreno-Grau¹, Oscar Sotolongo-Grau¹, Susana Ruiz¹, Laura Montrreal¹, Elvira Martín¹, Esther Pelejà¹, Francisco Lomeña³, Francisco Campos³, Assumpta Vivas4, Marta Gómez-Chiari⁴, Miguel Angel Tejero⁴, Joan Giménez⁴, Virginia Pérez-Grijalba², Marta Marquié¹, Gemma Monté-Rubio¹, Sergi Valero¹, Adelina Orellana¹, Lluis Tárraga¹, Manuel Sarasa², Agustín Ruiz¹, Mercè Boada¹, on behalf of the FACEHBI study ((1) Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain; (2) Araclon Biotech©. Zaragoza, Spain; (3) Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain; (4) Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain)

P57: Concordance of the Csf Abeta42/Abeta40 Ratio with Amyloid-Pet in the Biofinder Study. Oskar Hansson^1,2, Katharina Zink³, Simone Wahl³, Monika Widmann⁴, Sandra Rutz³, Maryline Simon⁵, Kaj Blennow^6,7, Erik Stomrud^1,2 ((1) Clinical Memory Research Unit, Lund University, Malmö, Sweden; (2) Memory Clinic, Skåne University Hospital, Malmö, Sweden; (3) Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany; (4) Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Mannheim, Germany; (5) Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland; (6) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; (7) Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden)

P64: Novel Pre-Analytical Protocol for Handling of Cerebrospinal Fluid Samples for the Analysis of Alzheimer'S Disease Biomarkers In Clinical Practice. Oskar Hansson^1,2, Erik Stomrud^1,2, Sandra Rutz³, Valeria Lifke³, Ekaterina Bauer³, Udo Eichenlaub³, Richard Batrla⁴, Ekaterina Manuilova⁴, Mehmet Can Mert⁴, Simone Wahl⁴, Kaj Blennow^5,6 ((1) Clinical Memory Research Unit, Lund University, Malmö, Sweden; (2) Memory Clinic, Skåne University Hospital, Malmö, Sweden; (3) Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany; (4) Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland; (5) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; (6) Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden)

P65: Serum-Based Proteins as Novel Biomarkers for the Diagnosis Of Alzheimer'S Disease. Shu Yu¹, Yue-Ping Liu² ((1) State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of LaboratoryMedicine, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province 710000, China; (2) Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China)

P66: Trem2 Dna Methylation: A Potential Biomarker or Therapeutic Target. Lynn Bekris¹ Rumana Akhter¹, Yvonne Shao¹, Maria Khrestian¹, Giana D'Aleo¹, Shane Formica¹, James B. Leverenz² ((1) Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; (2) Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio)

P73: Immune State in Cognitive Impairment of Aged and the Use of Actovegin and Ceraxone in Out-Patients Of Alzheimer'S Centre. Nataliya Mikhaylova¹, Lubov Androsova² ((1) Geriatric psyciatry Department, Mental health researc centre, Moscow, Russia; (2) Immunology laboratory, Mental health research centre, Moscow, Russia)

P78: Modifiable Alzheimer'S Risk Biomarkers. Christine Ganzer¹, Alon Seifan², Krista Ryon³, Elizabeth Maiche⁴ ((1) Hunter College, NY; (2) NeuroWell Free, Ft. Lauderdale, Florida; (3) Hunter College, NY; (4) NeuroWell Free, Ft. Lauderdale, Florida)

P81: Serum Nfl, Tau, Gfap and Uchl-1 in Alzheimer Disease Patients with Different Decline Profile. Mélissa Jacob^1,2,3, Aleksandra Maceski³, Stiene Rickaert³, Audrey Gabelle^1,2,4, Sylvain Lehmann^2,3 ((1) Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France; (2) Université de Montpellier, MUSE, Montpellier, France; (3) Inserm U1183 IRMB, Montpellier, France; (4) Inserm U1061, La Colombière Montpellier University Hospital, Montpellier, France)

P125: An Ultra-Sensitive Molecular Immunoassay for Quantification of Human Snap25 In Cerebrospinal Fluid. Eugeen Vanmechelen¹, Jeroen Vanbrabant¹, Naomi De Roeck², Maria Bjerke², Sebastiaan Engelborghs^2,3, Ann De Vos¹ ((1) ADx NeuroSciences NV, Ghent – Belgium; (2) Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp – Belgium; (3) Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp – Belgium)

P126: Plasma And Csf Biomarkers for the Diagnosis Of Alzheimer´S Disease in Adults With Down Syndrome. A Cross-Sectional Study. Maria Carmona-Iragui^1,2,3, Bessy Benejam², Susana Fernández², Laura Videla^1,2,3, Isabel Barroeta^1,3, Daniel Alcolea^1,3, Jordi Pegueroles^1,3, Laia Muñoz^1,3, Olivia Belbin^1,3; Jordi Clarimón^1,3, Mony John de Leon⁴, Sebastián Videla^2,5, Aleksandra Maleska Maceski⁶, Christophe Hirtz⁶, Constance Delaby⁶, Sylvain Lehmann⁶, Rafael Blesa^1,3, Alberto Lleó^1,3, Juan Fortea^1,2,3 ((1) Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau-Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Spain; (2) Barcelona Down Medical Center. Fundació Catalana de Síndrome de Down, Barcelona, Spain; (3) Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; (4) New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry. New York, USA; (5) Clinical Research Support Unit, Bellvitge University Hospital /Bellvitge Biomedical Research Institute (IDIBELL) /University of Barcelona, Barcelona, Spain; (6) Université de Montpellier, CHU de Montpellier, INSERM U1183. Montpellier, France)

P127: The Application of Polygenic Risk Score Analysis to Stratification of Subjects for Clinical Trials in Alzheimer'S Disease in Carriers and Non-Carriers of the Apoe4 Risk Allele. Richard Pither PhD³; Ganna Leonenko¹; Rebecca Simms¹, Paula Daunt³, Greg Davidso³, Alex Gibson³, Olusegun Oshota³, Maryam Shoai², Kevin Banks³, Simon M Laws⁴, Zsuzsanna Nagy⁶, John Hardy², Julie Williams^1,6, Valentina Escott-Price^1,6 ((1) Cardiff University, Cardiff, United Kingdom; (2) Cytox Ltd, UK, Oxford, United Kingdom; (3) UCL Institute of Neurology, London, United Kingdom; (4) Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; (5) University of Birmingham, United Kingdom; (6) Dementia Research Institute, Cardiff, United Kingdom)

P128: Do Short Aβ-Peptides Impact the Time Course of Cognitive Decline? An Adni Analysis. Markus von Kienlin¹, Paul Delmar¹, Katharina Buck², Charlotta Schärfe², Simone Wahl², Karlheinz Baumann², Irene Gerlach¹, Tania Nikolcheva¹ ((1) pRED NORD, Roche Innovation Center Basel -Switzerland; (2) Biostats and Data Management, Roche Innovation Center Munich -Germany)

P129: Sustained Attention and Memory Tasks with Concurrent Eeg Provide Potential Biomarkers for Mild Cognitive Impairment. SangYun Kim^1,2, Sungmin Kang³, Seong Soo A. An⁴, Young Chul Youn⁵ ((1) Department of Neurology, Seoul National University College of Medicine; (2) Clinical Neuroscience Center, Seoul National University Bundang Hospital; (3) PeopleBio Company; (4) Department of Bionano Technology,Gachon Medical Research Institute, Gachon University; (5) Department of Neurology, Chung-Ang University College of Medicine)

P130: Transcranial Magnetic Stimulation Predicts Cognitive Decline in Alzheimer'S Disease Patients. Giacomo Koch^1,2, Caterina Motta², Francesco Di Lorenzo², Maria Concetta Pellicciari², Sonia Bonnì², Silvia Picazio², Carlo Caltagirone², Alessandro Martorana³ ((1) Department of Behavioral and Clinical Neurology; (2) Santa Lucia Foundation IRCCS, Rome, Italy; (3) Univeristy of Tor Vergata, Rome, Italy)

P131: Non-Core Biomarkers (Neurofilament Light, Neurogranin, 14-3-3 And Ykl-40) in the Alzheimer'S Disease Continuum, Frontotemporal Dementia and Prion Diseases Diagnosis. Anna Antonell¹, Adrià Tort¹, José Ríos², Sergi Borrego¹, Mircea Balasa¹, Cristina Muñoz-García¹, Beatriz Bosch¹, Neus Falgàs¹, Lorena Rami¹, Kaj Blennow³, Henrik Zetterberg^4,5, José Luis Molinuevo¹, Albert Lladó¹, Raquel Sánchez-Valle¹ ((1) Alzheimer's disease and other cognitive disorders Unit. Hospital Clínic. IDIBAPS. Barcelona, Spain; (2) Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic. Barcelona. Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona; (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; (4) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; (5) Department of Molecular Neuroscience, University College London, London, UK)

P132: Amyloid Blood Biomarker Detect Alzheimer'S Disease. Klaus Gerwert (Ruhr-Universität Bochum, Bochum – Germany)

P133: Early Diagnosis of Mild Cognitive Impairment and Alzheimer´S Disease Based on Salivary Lactoferrin. Eva Carro¹, Gorka Orive²(1) Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain; (2) Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain)

P134: Exome-Sequencing in Patients with Early-Onset Alzheimer'S Disease And Frontotemporal Dementia: Causal Mutations And Genetic Variants in Risk Genes for Dementia. Anna Antonell¹, Raquel Sánchez-Valle¹, Neus Falgàs¹, Mircea Balasa¹, Debayan Datta², Lluís Armengol², Sergi Borrego¹, Guadalupe Fernández¹, Beatriz Bosch¹, Jaume Olives¹, Cristina Muñoz-García¹, María León¹, Magdalena Castellví¹, Adrià Tort¹, Albert Lladó¹ ((1) Alzheimer's disease and other cognitive disorders Unit. Hospital Clínic. IDIBAPS. Barcelona, Spain; (2) qGenomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat, Spain)

P135: The Future of Blood-Based Kinase Biomarkers in Alzheimer'S Disease. Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet (Center of Cognitive Neurology, Lariboisiere Hospital, AP-HP, University of Paris Diderot, Paris, France)

P136: A Prototype Simoa Assay Quantifying Plasma Amyloid Beta 1–42 and 1–40 Isoforms Can Differentiate Ad from Healthy Control Subjects. Charlotte E. Teunissen¹, Elisabeth Thijssen², Inge M. W. Verberk², Hugo Marcel Vanderstichele³, Hans Heijst², Harry Twaalfhoven², Kimberley Mauroo³, Philip Scheltens⁴, Erik Stoops³ ((1) Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands; (2) Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands; (3) ADx NeuroSciences, Gent, Belgium; (4) Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands)

P137: Serum-Based Proteins As Novel Biomarkers for the Diagnosis of Alzheimer'S Disease. Jacques Shu Yu¹, Yue-Ping Liu² ((1) State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province China; (2) Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province, China)

P138: Inflammatory Markers Tracking Cognitive and Biomarker Heterogeneity in Mci Stage of Alzheimer'S Disease. Jagan A Pillai^1,2,3, James Bena⁴, Lynn M Bekris⁵, James B Leverenz^1,2,3 ((1) Lou Ruvo Center for Brain Health; (2) Neurological Institute; (3) Department of Neurology; (4) Quantitiave Health Sciences; (5) Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA)

P139: The Pitfalls for Clinical Trials of the Use of Time Points Earlier Than 90 Min for the [18F]Mk-6240 Suvr Calculation. Tharick A. Pascoal MD¹, Sulantha Mathotaarachchi MSc ¹, Mira Chamoun², Joseph Therriault¹, Robert Hopewell², Gassan Massarweh², Andrea L. Benedet¹, Min Su Kang¹, Serge Gauthier¹, Pedro Rosa-Neto¹ ((1) Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada; (2) Montreal Neurological Institute, McGill University, Montreal, Canada)

Theme: Clinical trials: Cognitive and functional endpoints

P2: Objectively Measured Physical Activity and Cognitive Function. Hiroyuki Umegaki¹, Taeko Makino², Kazuki Uemura³, Hiroyuki Shimada⁴, Xian Wu Cheng⁵ ((1) MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan; (2) PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan; (3) Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan; (4) Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan; (5) PhDb, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan)

P3: D-Cycloserine Improves Difficult Discriminations in a Pattern Separation Task in Alzheimer'S Disease: Implications for Dentate Gyrus Activity And Neurogenesis. Pascal J. D. Goetghebeur¹, Keith A. Wesnes², Steven D. Targum³ ((1) Bracket LLC, Reading, UK; (2) Wesnes Cognition Ltd, Streatley on Thames, UK;. (3) Bracket LLC, Boston, US)

P8: A MULTICENTER, OPEN-LABEL, 24-WEEK FOLLOWUP STUDY FOR EFFICACY ON COGNITIVE FUNCTION OF DONEPEZIL IN BINSWANGER-TYPE SUBCORTICAL VASCULAR DEMENTIA. Jay Cheol Kwon¹, Eung Gyu Kim², Jae Woo Kim³, Oh Dae Kwon⁴, Bong Goo Yoo⁵, Nam-Gon Kim⁶, Nack Cheon Choi⁷, Seon young Ahn, Byung Hwa Lee⁸, Myong Jin Kang⁹, Dae Seob Choi¹⁰, The BKVD Study Group ((1) Department of Neurology, Changwon Fatima Hospital; (2) Inje University Pusan Paik Hospital; (3) Dong-A University Medical Center; (4) Daegu Catholic University Medical Center; (5) Kosin University Gospel Hospital; (6) Gimhae Jungang Hospital; (7) Gyeongsang National University Hospital; (9) Department of Radiology, Dong-A University Medical Center; (10) Gyeongsang National University Hospital)

P9: The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain Mri and Cognitive Decline in Seventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Studye. Jay Choel Kwon, Kyungsoo Lee, Yohan Jung, Sungrae Cho, Nack-cheon Choi (Changwon Fatima Hospital, Changwon, Korea, The Republic of Samsung Changwon Hospital, Changwon, Korea, The Republic of Gyeongsang National University Hospital, Chinju, Korea)

P19: Lanabecestat: Central Monitoring of Rater Performance and Error Characteristics of Efficacy Assessments in the Amaranth Study. Alette M. Wessels¹, Lisle R. Kingery², Edward I. Bartolic², Laura E. Nickell¹, Jamie A. Mullen³, John R. Sims¹ ((1) Eli Lilly and Company, Indianapolis, IN, USA; (2) Cogstate, New Haven, USA; (3) AstraZeneca Pharmaceuticals, Cambridge, MA, USA)

P25: Effects of Sex, Educational Background, and Ckd Grading on Cognitive and Functional Decline in Japanese Adni Study. Atsushi Iwata¹, Ryoko Ihara², Kazushi Suzuki², Takeshi Iwatsubo² and the Japanese ADNI1¹ ((1) Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan; (2) Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital Tokyo, Japan)

P26: A German Version of the “Five Word Test” – Discriminating Patients with Mild Cognitive Impairment/Mild Alzheimer'S Disease, Healthy Controls and Patients With Depression. Hausner L, Dinu-Biringer R, Frölich L (Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany)

P27: Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment. Shim YongSoo, Jung San (Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea; Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea)

P53: Mmse Screening Data Quality for Alzheimer'S Disease Studies Across Countries. Jordan Mark Barbone¹, Todd M. Solomon^1,2, H. Todd Feaster¹, Macarena Garcia-Valdecasas Colell³, David S. Miller¹ ((1) Bracket, Wayne, PA, USA; (2) Boston University School of Medicine, Boston, MA, USA; (3) Bracket, Reading, UK)

P67: The Presence of Identical Scoring on the Mmse and Adcs-Adl in Alzheimer'S Disease Clinical Trials Using Enhanced Ecoa Devices. Todd M. Solomon², Jordan Mark Barbone¹, Sarah M. Karas¹, Danielle T. DiGregorio¹, Michael R. Maddock¹, David M. Miller¹, H. Todd Feaster¹ ((1) Bracket, Wayne, PA, USA; (2) Boston University School of Medicine, Boston, MA USA)

P69: Neuroplasticity-Based Visual Alertness Training and Improvements in Declining Executive Functions in Healthy Older Adults.. Thomas Van Vleet¹, Joseph DeGutis², Michelle Voss³ ((1) Research and Development, Posit Science, San Francisco, CA, USA; (2) School of Medicine, Harvard University, Boston, MA, USA; Boston VA, Boston, MA, USA; (3) Psychology Department, University of Iowa, Iowa City, IA, USA)

P74: Predictive Value and Test-Retest Reliability of the Tablet-Based Brief Assessment of Cognition (Bac App) for Assessment of Cognition in Aging: Preliminary Findings From An Ongoing Normative Study. Anzalee Khan^1,2, Danny Ulshen¹, Alexandra Atkins¹, Danela Balentin¹, Adam Vaughan¹, Heather Dickerson¹, Brenda L. Plassman³, Kathleen A. Welsh-Bohmer³, Rich Keefe^1,3 ((1) NeuroCog Trials, Durham, NC, USA; (2) Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA; (3) Duke University, Durham, NC, USA)

P77: Clinical And Amyloid Screen Failure Rates in Episodic Memory Measures of Early Ad Trials. Selam Negash¹, Christopher Weber¹, Christopher Randolph^1,2 ((1) MedAvante-ProPhase; (2) Loyola University Medical Center)

P83: Determinants of Care Refusal: From Patients Suffering from Dementia to Their Caregivers Characteristics. Gaëstel Y, Cerda S (Memory Center, Bagatelle Hospital, Talence, France)

P135: The Future of Blood-Based Kinase Biomarkers in Alzheimer'S Disease. Sietske A. M. Sikkes^1,2, Mark A. Dubbelman¹, Merike Verrijp¹, Gonzalo Sánchez Benavides³, David Facal⁵, Bruno Dubois⁴, Wiesje M. van der Flier^1,2, Hanna Jokinen⁶, Cristina Lojo-Seoane⁵, José Luís Molinuevo³, Arturo X. Pereiro Rozas⁵, Craig Ritchie⁷, Magdalini Tsolaki^8,9, Ya-Huei Wu¹⁰, Stelios Zygouris^8,11, Stephane Epelbaum⁴, Philip Scheltens¹ ((1) Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands; (2) Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; (3) BarcelonaBeta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain; (4) Hôpital Pitié-Salpêtrière, IM2A, PARIS, France; (5) Department of Developmental Psychology, University of Santiago de Compostela, Spain; (6) Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland; (7) University of Edinburgh, United Kingdom ; (8) 1st Department of Neurology, Aristotle University of Thessaloniki, Greece; (9) Greek Association of Alzheimer's Disease and Related Disorders, Greece; (10) Broca Hopital, Paris, France; (11) Network Aging Research, University of Heidelberg, Germany)

P141: Clinical Effects of Oral Tramiprosate in Apoe4/4 Homozygotes with Mild Alzheimer'S Disease (Ad): Responder Analyses of Cognitive And Functional Outcomes. Susan Abushakra¹, Bruno Vellas², Serge Gauthier³, Anton Porsteinsson⁴, Carl Sadowsky⁵, Aidan Power¹, Larry Shen⁶, Lu Wang⁶, Tim Lin⁶, John Hey¹, Martin Tolar ¹ ((1) Alzheon, Inc., Framingham, MA, USA; (2) University of Toulouse, Toulouse, France; (3) McGill University, Montreal, Canada; (4) University of Rochester, Rochester, New York; (5) Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida 6Pharmapace, Inc., San Diego, CA)

P142: Exploring Genetic Associations of Alzheimer'S Disease Loci with Mild Cognitive Impairment Neurocognitive Endophenotypes. Impact on Cognitive and Functional Endpoints. Ana Espinosa¹, Begoña Hernández-Olasagarre¹, Sonia Moreno-Grau1, Luca Kleineidam^2,3,4, Stefanie Heilmann^5,6, Isabel Hernández¹, Steffen Wolfsgruber^2,7, Holger Wagner⁷, Maitée Rosende-Roca¹, Ana Mauleón¹, Liliana Vargas¹, Asunción Lafuente¹, Octavio Rodríguez-Gómez¹, Carla Abdelnour¹, Silvia Gil¹, Marta Marquié¹, Miguel A. Santos-Santos¹, Ángela Sanabria¹, Gemma Ortega¹, Gemma Monté¹, Alba Pérez¹, Marta Ibarria¹, Susana Ruiz¹, Johannes Kornhuber⁸,Oliver Peters⁹, Lutz Frölich¹⁰, Michael Hüll¹¹, Jens Wiltfang¹², Martin Scherer¹³, Tobias Luck¹⁴, Steffi Riedel-Heller¹⁴, Laura Montrrea^l1, Pilar Cañabate¹, Mariola Moreno¹, Silvia Preckler¹, Nuria Aguilera¹, Itzíar de Rojas¹, Adela Orellana¹, Montserrat Alegret¹, Sergi Valero¹, Markus M Nöthen^2,3, Michael Wagner^4,5, Frank Jessen^4,5,7, Wolfgang Maier^4,5, Lluis Tárraga¹, Mercè Boada¹, Alfredo Ramírez^2,3,4,5, Agustín Ruiz¹ ((1) Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain; (2) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; (3) Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, German; (4) Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany; (5) Institute of Human Genetics, University of Bonn, Bonn, Germany; (6) Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany; (7) Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; (8) Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany; (9) Department of Psychiatry, Charité University Medicine, Berlin, Germany; (10) Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; (11) Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany; (12) Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany; (13) Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; (14) Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany)

P143: Baseline Characterization of the European Prevention of Alzheimer'S Dementia (Epad) Longitudinal Cohort Study (LCS). Michael T. Ropacki¹, John Harrison^2,3, Joel Kramer³, Christopher Randolph⁴, Jeffrey Kaye⁵, Bruce Albala⁶, Karen Ritchie^7,8,9 ((1) Strategic Global Research & Development, Half Moon Bay, USA; (2) Metis Cognition Ltd, UK; (3) Alzheimer Center VUmc, Amsterdam, Netherlands; (4) Department of Neurology Memory and Aging Center, University of California at San Francisco – San Francisco, USA; (5) Department of Neurology, Loyola University Medical Center, Maywood, USA; (6) Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA; (7) Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatrie, Montpellier, France; (8) Faculty of Medicine, University of Montpellier, Montpellier, France; (9) Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK)

P144: Two Distinct Modelling Approaches Of Cognitive Decline and Time to Diagnosis of Mci/Dementia to Inform Study Design and to Improve Risk Prediction In Preclinical Alzheimer´S Disease. Angelika Caputo¹, Ana Graf¹, Cristina Lopez Lopez¹, Valery Risson¹, Giulia Lestini¹, Neva Coello¹, Amy Racine¹, Ines Paule¹, Luyuan², Helene Karcher³ ((1) Novartis Pharma AG, Basel, Switzerland; (2) Analytica Laser, a Certara company, Paris, France (3) Analytica Laser, a Certara company, London, UK)

P145: Ability of an Online Object Pattern Separation Test to Detect Potential Disruptions to Hippocampal Neurogenesis Associated with Ageing, Gender, Lifestyle and Disease in a Large Cohort of Older Adults. Keith A. Wesnes^1,2, Helen Brooker^1,2, Clive Ballard¹, Dag Aarsland³, Zunera Khan³, Maria Megalogeni³, Anne Corbett¹ ((1) University of Exeter Medical School, University of Exeter, Exeter, UK; (2) Wesnes Cognition Ltd, Streatley on Thames, UK (3) King's College London, London, UK)

P146: Comparison of Sleep Measurements From Actigraphy to Self-Reported Sleep Diaries. Kirsi Kinnunen¹, Richard Joules¹, Janet Munro¹, Iain Simpson¹, Robin Wolz^1,2, Yves Dauvilliers³ ((1) IXICO Plc, London, UK; (2) Imperial College London, London -UK; (3) Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM 1061 -France)

P147: Using Dctclock'S Clinically-Interpretable Artificial Intelligence for Differentiating Cognitively Healthy Subjects From Amnestic Mild Cognitive Impairment and Probable Alzheimer'S Disease. William Souillard-Mandar¹, Braydon Schaible¹, Randall Davis^1,2, Rhoda Au³, Dana Penney^1,4 ((1) Digital Cognition Technologies, Inc., Waltham, MA, USA; (2) MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA; (3) Boston University Schools of Medicine and Public Health, Boston, MA, USA; (4) Lahey Hospital and Medical Center, Burlington, MA, USA)

P148: Advancing Clinical and Biomarker Research in Ad: The Lead Study. Liana G. Apostolova, Paul Aisen, Ani Eloyan, Anne Fagan, Tatiana Foroud, Constantine Gatsonis, Clifford Jack, Joel Kramer, Robert Koeppe, Andrew Saykin, Arthur Toga, Prashanthi Vemuri, Gregory Day, Neill Graff-Radford, Lawrence Honig, David Jones, Sterling Johnson, Joseph Masdeau, Mario Mendez, Chiadi Onyike, Emily Rogalski, Steve Salloway, David Wolk, Thomas Wingo, Maria Carrillo, Brad Dickerson, Gil Rabinovici

P149: Measuring Pre-Clinical Cognitive Decline Over Time: Separating and Combining Alzheimer's Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores. Suzanne Hendrix¹, Noel Ellison¹, Jessica B. Langbaum², Kewei Chen³, David A. Bennett⁴ ((1) Pentara Corporation, Millcreek, UT, USA; (2) Arizona Alzheimer's Consortium, Phoenix, AZ, USA; (3) University of Arizona, Tucson, AZ, USA; (4) Rush University, Chicago, IL, USA)

Theme: Cognitive assessment and clinical trials

P6: Evaluation of Titers of Antibodies Against Peptides of Subunits Nr1 and Nr2B of Glutamate Receptor By Enzyme-Linked Immunosorbent Assay in Psychiatric Patients With Anti-Thyroid Antibodies. Takahiro Ikura (Yokohamacity Univercsity Psychiatry)

P24: Clinical Correlates of Types of Memory Complaints in Mild Cognitive Impairment. Seon Young Ryu, Sang Bong Lee, Taek Jun Lee, Yu Jin Jung (Neurology Department, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea)

P29: A Comparison Between Brief Episodic Memory and Semantic Memory Tasks Within a Screening Test for Mild Cognitive Impairment. Pamela Voccia, Katherine Kruczek (Bioclinica Research, The Villages, FL USA)

P34: A Multicentre, Pilot Study to Evaluate an Augmented Reality Test (Altoidatm) for Mild Cognitive Impairment Detection. Mircea Balasa^1,2, Adrià Tort-Merino¹, Ioannis Tarnanas^2,3, David Bartrés-Faz⁴, Rory Boyle⁵, Laura Rai⁵, Rob Whelan^2,5, Raquel Sanchez-Valle¹ ((1) Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain; (2) Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland; (3) Altoida AG, Lucerne, Switzerland; (4) Departament de Medicina, Faculty of Medicine and Health Sciences, University of Barcelona; (5) School of Psychology, Trinity College Dublin, Dublin, Ireland)

P41: Cognitive Impairment Under Treatment With 2Nd and 3Rd Generation Antihistamines in Elderly Subjects. Georg Adler, Nadja Baumgart (Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany)

P42: Using Bayesian Methods to Model Normative Cantab Cognition Data Across Adulthood. Pasquale Dente¹, Elizabeth Baker¹, Jack Cotter¹, Francesca Cormack¹, Jennifer H Barnett^1,2 ((1) Cambridge Cognition Limited, Cambridge, UK; (2) University of Cambridge, Cambridge, UK)

P47: Predicting The Course of Alzheimer'S. Samuel Iddi^1,3, Dan Li¹, Wesley K Thompson², Michael S. Rafii¹, Paul S. Aisen¹, and Michael C Donohue¹ ((1) ATRI, University of Southern California, San Diego, CA, United States; (2) Department of Family Medicine and Public Health, University of California, San Diego, USA; (3) Department of Statistics, University of Ghana, Legon-Accra, Ghana)

P48: Impaired Delayed Recall on the International Shopping List Task Predicts Amyloid Positivity and Longitudinal Decline in Cdr-Sb Scores In Mci. Sharon Rosenzweig-Lipson¹, Richard Mohs¹, Paul Maruff², Michela Gallagher^1,3, Arnold Bakker³ ((1) Agenebio, Inc. 1101 E. 33rd Street, Suite C310, Baltimore, MD, USA; (2) Cogstate, Ltd., Melbourne, Victoria, Australia; (3) Johns Hopkins University, Baltimore, MD, USA

P49: Mmse Screening Data Quality for Alzheimer'S Disease Studies Across Countries. Jordan Mark Barbone¹, Todd M. Solomon^1,2, H. Todd Feaster¹, Macarena Garcia-Valdecasas Colell³, David S. Miller¹ ((1) Bracket, Wayne, PA, USA; (2) Boston University School of Medicine, Boston, MA, USA; (3) Bracket, Reading, UK)

P50: Affective Variability Predicts Cognitive Fluctuation And Decline in Older Adults. Edward Zamrini¹, Michael Malek-Ahmadi², Kathy O'Connor¹, Sharon Schofield¹ ((1) Banner Sun Health Research Institute, Sun City, USA; (2) Banner Alzheimer's Institute, Phoenix, USA)

P51: Validation Of The Geriatric Depression Scale in the Elderly Korean With Alzheimer'S Disease. Moon Ho PARK, Do-Young Kwon (Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea)

P52: Can Tmt-Black and White Predict the White Matter Hyperintensity of Mri in the Community Based Elderly?

P55: CANTAB TESTS PREDICT CHANGE IN GLOBAL FUNCTIONING IN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT. Elizabeth Baker¹, Peter Annas¹, Giovanni B. Frisoni^2,19, David Bartres-Faz³, Beatriz Bosch³, José Luis Molinuevo³, Mira Didic^4,5, Francesca De Anna^4,5, Lucilla Parnetti⁶, Nicola Salvadori⁶, Jens Wiltfang^7,15, Flavio Nobili⁸, Nicola Girtner⁸, Peter Schönknecht⁹, Pieter J. Visser¹⁰, Paolo M. Rossini¹¹, Paola Chiovenda¹¹, Pierre Payoux¹², Andrea Soricelli¹³, Marco Salvatore¹³, Magda Tsolaki¹⁴, Jill C. Richardson¹⁶, Régis Bordet¹⁷, Olivier Blin¹⁸, Gianluigi Forloni20 on behalf of the PharmaCog Consortium ((1) Cambridge Cognition Ltd, Bottisham, Cambridge, UK; (2) Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy; (3) Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, University of Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain; (4) Aix-Marseille Universite, INSERM, France; (5) Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France; (6) Clinica Neurologica, Universita di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy; (7) Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany; (8) Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy; (9) Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany; (10) Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands; (11) Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy; (12) ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; (13) SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy ;(14) Third Neurologic Clinic, Medical School, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; (15) Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany; (16) Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK; (17) University of Lille, Inserm, CHU Lille, U1171 – Degenerative and Vascular Cognitive Disorders, Lille, France; (18) Aix-Marseille University, UMR Inserm 1106, Institute Neurosciences Sytemes, Marseille, France; (19) Memory Clinic and LANVIE – Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland; (20) Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy)

P63: Validating Simulated Cognition Trajectories Based on Adni Against Trajectories from the National Alzheimer's Coordinating Center (Nacc) Dataset. Ali Tafazzoli¹, Josh Weng², Kelly Sutton³, Michal Litkiewicz³, Ameya Chavan¹, Mira Krotneva⁴,Anuraag Kansal¹ ((1) Evidera, Bethesda, MD, USA; (2) Evidera, Waltham, MA, USA; (3) Evidera, London, UK; (4) Evidera, Montreal, Canada)

P68: Recruitment Using the Dctclocktm. Daniel Lawler, Stephen Thein (Pacific Research Network Inc., San Diego, CA, USA)

P70: Strategy or Symptom: Semantic Clustering and Risk of Alzheimer'S Disease. Jamie Ford, Bang Zheng, Barbara Hurtado, M.A, CPsychol, Chi Udeh-Momoh, Geraint Price (Imperial College London, UK)

P72: Tau is Associated With Longitudinal Memory Decline in Healthy Subjects: The Need for an Early Detection of Subtle Cognitive Changes. Adrià Tort-Merino¹, Jaume Olives¹, María León¹, Claudia Peñaloza², Natalia Valech¹, Petra Grönholm-Nyman³, Pablo Martínez-Lage⁴, Juan Fortea^5,6, José Luis Molinuevo^1,7, Raquel Sánchez-Valle^1,8, Matti Laine¹, Antoni Rodríguez-Fornells^2,9,10, Lorena Rami^1,8 ((1) Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain; (2) Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; (3) Department of Psychology, Åbo Akademi University, FIN-20500 Turku, Finland; (4) Neurología, Fundación CITA-Alzhéimer Fundazioa, Centro de Investigación y Terapias Avanzadas, San Sebastián, Guipúzcoa, España; (5) Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Institute of Biomedical Research, Barcelona, Spain; (6) Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas Neurodegenerativas, CIBERNED, Spain; (7) Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; (8) August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; (9) Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; (10) Department of Cognition, Development and Education Psychology, Campus Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain)

P87: Clinical Effects of Oral Tramiprosate in Apoe4/4 Homozygotes with Mild Alzheimer'S Disease (Ad): Responder Analyses Of Cognitive and Functional Outcomes. Alexandra S. Atkins¹, Anzalee Khan^1,2, Daniel Ulshen¹, John Harrison^3,4, Brenda L. Plassman⁵, Kathleen A. Welsh-Bohmer⁵, Richard S.E. Keefe^1,6 ((1) NeuroCog Trials, Durham, NC; (2) Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY; (3) Alzheimer Center, VUmc, Amsterdam, The Netherlands; (4) IoPPN, King's College, London, UK; (5) Duke University Bryan ADRC, Durham, NC; (6) Duke University Medical Center, Durham, NC; (7) Duke University Medical Center, Durham, NC)

P88: Severe Cognitive Impairment in Older Adult Heart Failure Patients: Preliminary Findings from the Deus Ex Machina Study. Emília Moreira¹, Sónia Martins^1,2, Luís Filipe Azevedo^1,3, José SilvaCardoso^1,4,5, Lia Fernandes^1,2,6 ((1) Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto -Portugal; (2) Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto -Portugal; (3) Department of Community Medicine, Information and Health Decision Sciences/MEDCIDS, Faculty of Medicine, University of Porto -Portugal; (4) Department of Medicine, Faculty of Medicine, University of Porto -Portugal; (5) Department of Cardiology S. João Hospital Center, Porto -Portugal; (6) Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto -Portugal)

P89: The Effect of Dizziness in Patients with Cognitive Impairments. Seunghee Na, In-Uk Song (Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea, Incheon, Korea)

P151: Selection of Depression-Specific Dementia Cases with Replication in Two Cohorts. Donald R. Royall1–4, Raymond F. Palmer3 ((1) Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA; (2) Department of Medicine, UTHSCSA, San Antonio, Texas, USA; (3) Department of Family & Community Medicine. UTHSCSA, San Antonio, Texas, USA; (4) South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA)

P152: Selection of Senility-Specific Dementia Cases with Replication in Two Cohorts. Donald R. Royall1–4, Raymond F. Palmer3 ((1) Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA; (2) Department of Medicine, UTHSCSA, San Antonio, Texas, USA; (3) Department of Family & Community Medicine. UTHSCSA, San Antonio, Texas, USA; (4) South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA)

P153: Assessment And Speech-Language Intervention Program in Non-Fluent Primary Progressive Aphasia: A Case Study. Beatriz Valles-González¹, Vicent Rosell-Clari^1,2 ((1) Speech and Language Pathology Clinic. Lluís Alcanyís Foundation-Universitat de Valencia; (2) Basic Psychology Department. Universitat de Valencia)

P154: Prediction Of Apoe Ε4 Burden from Cognitive Assessment. Royall DR1–4, Palmer RF3 for the Alzheimer's Disease Neuroimaging Initiative* ((1) Departments of Psychiatr1, (2) Medicine, (3) amily & Community Medicine, (4) The University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC))

P155: Clinical Effects Of Oral Tramiprosate in Apoe: Could Telemedicine Improve Neurocognitive Disorders Detection and Diagnosis in Nursing Home? Armelle Leperre-Desplanques¹, Isabelle Hauger², Sylvain Gaulier¹, Antonis Politis³, Shima Mehrabian⁴, Audrey Maillet¹, Pierre Krolak-Salmon¹ ((1) Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMR1028, CNRS UMR 5292, Lyon University, France; (2) Résidence Talanssa, Talence, France; (3) National and Kapodistrian University of Athens, Athens, Greece; (4) Clinic of Neurology, UH “Alexandrovska”, Medical University, Sofia, Bulgaria)

P156: Cognitive Blackouts in Mild Cognitive Impairment of the Amnestic Type and Mild Alzheimer'S Dementia. Georg Adler, Agnies Marczak, Jana Binder, Katharina Gnosa (Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany)

P157: Feasibility of the Neuropsychological Battery Camcog-Ds for the Detection of Cognitive Decline in People with Down Syndrome. Laura Videla^1,2,3, Bessy Benejam¹, María Carmona-Iragui^1,2,3, Susana Fernández¹, Isabel Barroeta^1,2,3, Sebastián Videla², Alberto Lleó^2,3, Rafael Blesa^2,3, Juan Fortea1,2,3 ((1) Alzheimer Unit -Down, Down Medical Center, Fundació Catalana Síndrome de Down; (2) Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau. Biomedical Research Institute of Sant Pau. Universitat Autònoma de Barcelona (3) Central Biomedical Research Center (CIBERNED))

P158: Distinct Patterns of Cognitive Decline Between Early-Onset Alzheimer'S Disease and Late-Onset Alzheimer'S Disease. Adrià Tort Merino, Jaume Olives, Neus Falgàs, Mircea Balasa, Magda Castellví, Sergi Borrego, Beatriz Bosch, María León, Ana Salinero, Guadalupe Fernández, Anna Antonell, Raquel Sánchez-Valle, Lorena Ramí, Albert Lladó (Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain)

P159: High Level of Plasmatic Amyloid Aβ 1–40 Increase The Risk Of Cognitive Decline in 3C Study with 14 Years of Follow-Up. Audrey Gabelle^1,2,3, Laure-Anne Gutierrez^2,3, Thibault Mura ^2,3, Jean-François Dartigues^4,5, Olivier Rouaud⁶, Jean-Charles Lambert^7,8,9,10, Catherine Helmer^4,5, Claudine Berr³ ((1) Memory Research and Resources Center, Montpellier University Hospital, Montpellier; (2) Inserm U1061, La Colombière Hospital, Montpellier; (3) University of Montpellier, MUSE University, Montpellier; (4) Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France; (5) CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France; (6) CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France; (7) CHRU de Lille, Lille, France; (8) INSERM U744, Lille, France; (9) Institut Pasteur de Lille, Lille, France; (10) Université de Lille Nord de France, Lille, France)

P160: Evidence That Regularly Performing Word or Number Puzzles Could Help Protect Against Cognitive Decline in a Large Cohort of Adults Aged 50 to 92. Keith A. Wesnes^1,2, Helen Brooker^1,2, Clive Ballard¹, Adam Hampshire³, Dag Aarsland⁴, Zunera Khan⁴, Rob Stenton⁵, Maria Megalogeni⁴, Anne Corbett¹ ((1) University of Exeter Medical School, University of Exeter, Exeter, UK; (2) Wesnes Cognition Ltd, Streatley on Thames, UK; (3) Imperial College London, London, UK; (4) King's College London, London, UK; (5) Manta software, Cambridge, UK)

P161: Is The Presence of Neuropsychiatric Symptoms in the 5 Domains of the Mild Behavioural Impairment Checklist (Mbi-C) Associated with the Quality of Core Aspects of Cognitive Function in Older Adults? Keith A. Wesnes^1,2, Helen Brooker^1,2, Byron Creese¹, Zahinoor Ismail³, Zunera Khan⁴, Maria Megalogeni⁴, Anne Corbett^1, Adam Hampshire⁴, Dag Aarsland⁴, Clive Ballard¹ ((1) University of Exeter Medical School, University of Exeter, Exeter, UK; (2) Wesnes Cognition Ltd, Streatley on Thames, UK; (3) University of Calgary, Calgary, Canada; (4) King's College London, London, UK; (5) Imperial College London, London, UK)

P162: Using Graphical Hierarchical Bayesian Cognitive Process Models Applied to Common Memory Tests to Detect Ad Pathology Within Normal Subjects. William R. Shankle^1,2,3, Junko Hara^1,3, Jason R. Bock¹, Dennis Fortier¹, Tushar Mangrola¹, Michael Lee², Gregory E. Alexander², William H. Batchelder², Ronald C. Petersen⁴, Walter Kremers⁴ ((1) Medical Care Corporation, Newport Beach, CA, USA; (2) Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA; (3) Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA; (4) Mayo Clinic, Rochester, MN, USA)

Theme: Behavioral disorders and clinical trials

P32: Effect Of Memantine on Behavioral and Psychological Symptoms of Dementia (Bpsd) of Alzheimer'S Disease -Study of Changes in Cerebral Blood Flow By Spect Imagingaims. Kiyoshi Kanaya¹, Shine Abe² ((1) MD, Geriatric medicine, Tokyo Medical University Hachioji medical center; (2) MD, Geriatric medicine, Tokyo Medical University Hachioji medical center)

P37: Clusterization of Behavioral and Psychological Symptoms of Dementia (Bpsd). Timofey L. Galankin, MD, PhD² , Anton Y. Bespalov^1,2, Hans J. Moebius1 ((1) EXCIVA, Am Aukopf 14/1, Heidelberg 69118, Germany; (2) Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, 6/8 Lev Tolstoy Str., St. Petersburg 197022, Russia)

P43: The Effect of Dizziness in Patients with Cognitive Impairments. Seunghee Na, MD, In-Uk Song, (Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea, Incheon, Korea)

P163: A Multicenter, Randomized Trial to Assess Efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-Care). Jihye Hwang¹, Geon-Ha Kim², Hae-Ri Na³, Soo-Jin Cho⁴, Kyung-Ho Yu⁵, Do Hoon Kim⁶, Jae-Hong Lee⁷, Seong-Hye Choi⁸ ((1) Department of Neurology, Keimyung University School of Medicine; (2) Department of Neurology, Ewha Womans University School of Medicine; (3) Department of Neurology, Bobath Memorial Hospital; (4, 5, 6) Hallym University School of Medicine; (7) University of Ulsan College of Medicine, Department of Neurology, (8) Inha University School of Medicine)

Theme: Health economics and clinical trials

P17: Effect Of Physical Activity on the Progression of Alzheimer'S Disease: The Credos Study. Seong Hye Choi¹, Jee Hyang Jeong², Eun-Joo Kim³, Kyung Won Park⁴, Bora Yoon⁵, Soo Jin Yoon⁶, Yang-Ki Minn⁷, Young Ju Suh⁸ ((1) Department of Neurology, Inha University School of Medicine, Incheon, South Korea; (2) Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea; (3) Department of Neurology, Pusan National University School of Medicine, Busan, South Korea; (4) Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea; (5) Department of Neurology, College of Medicine, Konyang University, Daejeon, South Korea; (6) Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea; (7) Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea; (8) Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea)

P40: The Survey for Current State and Dognition of Activities of Daily Living in Korean Dementia Patients. Kee Hyung Park¹, Chan-Nyoung Lee², Hojin Choi³ ((1)Department of Neurology , Gachon University, Gil Medical Center, Incheon, Korea; (2) Department of Neurology, Korea University College of Medicine, Seoul, Korea; (3) Department of Neurology, Hanyang University Guri Hospital, Guri, Korea)

P58: Young Onset Diseases Care Patways. Parcours Des Malades Alzheimer Et Apparentes Jeunes -Parmaaj. Adeline Rollin-Sillaire^1,2, Brigitte Leprince³, Catherine Adnet-Bonte³, Laetitia Breuilh², Florence Pasquier^1,2 ((1) Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France; (2) Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille; (3) Meotis, Centre Hospitalier Universitaire de Lille, France)

P164: Dutch Online Registry for Recruitment of Participants for Dementia Studies. Marissa D. Zwan¹, Derek Flenniken^2,3, Shannon Finley², Aaron Ulbricht^2,3, Rachel Nosheny^2,3, Wiesje M. van der Flier¹, Philip Scheltens¹, Diana Truran-Sacrey², Michael W. Weiner^2,3, Niels D. Prins¹ ((1) Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam -the Netherlands; (2) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center, San Francisco -USA; (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco -USA)

Theme: Epidemiology and clinical trials

P31: Awareness of Alzheimer's Dementia as Their Own Disease in Asian Countries. San Jung, YongSoo Shim, SangYun Kim (Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea; Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Seoul, Korea; Department of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea)

P38: Subjective Memory Complaints are Related to the Social Participation and Leisure Activities: Toyoake Integrated Care Study (Toics). Hajime Takechi¹, Akira Tsuzuki², Komaki Matsumoto³, Hiroyuki Nishiyama4, Masatoshi Ogawa3, Yoshikiyo Kanada² ((1) Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan; (2) Faculty of rehabilitation, School of Health Science, Fujita Health University, Aichi, Japan; (3) Department of community care, Toyoake city municipal] office, Aichi, Japan; (4) Gyosei Corporation, Tokyo, Japan)

P46: Alzheimer'S Disease Drug Development Pipeline: 2018. Jeffrey Cummings¹, Garam Lee¹, Aaron Ritter¹, Kate Zhong² ((1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; (2) Global Alzheimer Platform, Washington, D.C., USA)

P165: Association Between Amyloid Status and Multiple Chronic Diseases in European Prevention of Alzheimer'S Dementia (Epad): Network and Cluster Analyses. Lucy E Stirland¹, Tom C Russ^1,2, Graciela Muniz Terrera, ¹, Craig W Ritchie¹ ((1) Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK; (2) Alzheimer Scotland Dementia Research Centre, Edinburgh, UK)

P166: Concord-Ad: An International Network of Cohorts for Better Understanding Alzheimer'S Disease. Samantha C Burnham¹, Preciosa M Coloma², Teresa J. Christainson³, Jean-François Dartigues^4,5, Rachelle Doody⁶, Oskar Hansson⁷, Catherine Helmer^4,8, Joseph S Kass⁹, Colin L Masters¹⁰, Sebastian Palmqvist^7,11, Valory N Pavlik⁹, Ronald C. Petersen^3,12, Rosebud O. Roberts^3,12, Maria Vassilaki³, Barbara Schauble¹³, Mary Sano^14,15 ((1) eHealth, CSIRO Health & Biosecurity, Melbourne, Australia; (2) Product Development Personalised Health Care – Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland; (3)Department of Neurology, Mayo Clinic, Rochester, MN, USA; (4) Bordeaux University, Bordeaux, France; (5) INSERM, ISPED, Centre INSERM U897-Epidémiologie-Biostatistique, Bordeaux, France; (6) F. Hoffmann-La Roche Ltd, Basel, Switzerland; (7) Clinical Memory Research Unit, Lund University, Malmö, Sweden; (8) INSERM U897, BORDEAUX, France; (9) Baylor College of Medicine, Houston, TX, USA; (10) The Florey Institute of Neuroscience and Mental Health, Parkville, Australia; (11) Department of Neurology, Skåne University Hospital, Lund, Sweden; (12) Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA; (13) Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland; (14) Department of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA; (15) James J. Peters VA Medical Center, Bronx, NY, USA)

P167: Cognitive and Brain Structural Correlates of Insomnia Symptoms in Middleaged Healthy Adults. Oriol Grau-Rivera¹, Juan Domingo Gispert^1,2, Grégory Operto¹, Carles Falcóna², Raffaele Cacciaglia¹, Gonzalo Sánchez-Benavides¹, Anna Bugulat¹, Nina Gramunt^1,3, Gemma Salvadó¹, Marc Suárez-Calvet¹, Carolina Minguillón¹, Karine Fauria¹, José Luis Molinuevo^1,3,4 ((1) Barcelonaβeta Brain Research Center, Catalonia, Spain; (2) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain; (3) CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain; (4) Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain)

P168: A Phase Ii Randomized Clinical Trial of High-Dose Versus Standard-Dose Vitamin D3 in an Ethnically Diverse Sample of Older Adults. John Olichney¹, Charlie DeCarli¹, Joshua W Miller², David Johnson¹, Sarah Tomaszewski-Farias¹, Bruce Hammock³, Brittany Dugger⁴, Lee-Way Jin⁴, Mary McPhail-Ciufo¹, Robert Soohoo⁵, Dan Mungas¹, Danielle Harvey⁶ ((1) Neurology Department, University of California Davis, Sacramento, CA, USA; (2) Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ; (3) Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA; (4) Pathology Department, University of California Davis, Sacramento, CA, USA; (5) Psychology Department, University of California Davis, Davis, CA, USA; (6) Department of Public Health Sciences, University of California Davis, Davis, CA, USA)

Theme: Animal model and clinical trials

P102: Concussive Head Injury Exacerbates Alzheimer'S Disease Brain Pathology. Superior Neuroprotection By Co-Administration of Tio2 Nanowired Cerebrolysin Together With Antibodies to Neuronal Nitric Oxide Synthase and Mesenchymal Stem Cells. Hari Shanker Sharma¹, José V Lafuente², Dafin F Mureseanu³, Rudy J Castellani⁴, Mark A Smith⁵, Ala Nozari⁶, Ranjana Patnaik⁷, Z Ryan Tian⁸, Asya Ozkizilcik⁹, Stephen D Skaper¹⁰, Herbert Mössler¹¹, Aruna Sharma¹ ((1) International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain; (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; a“RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania; (4) University of Maryland, Dept. of Pathology, Baltimore, MD, USA; (5) Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA; (6) Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA; (7) School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India; (8) Dept. Chemistry & Biochemistry &; (9) Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA; (10) Department of Pharmacology and Anesthesiology, University of Padua, Faculty of Medicine, Padua, Italy; (11) Ever NeuroPharma, Oberburgau, Austria)

P103: Sleep Deprivation Aggravates Alzheimer'S Disease Brain Pathology. Enhanced Neuroprotection By Nanowired Delivery of Cerebrolysin with Alpha Melanocyte Stimulating Hormone and Antibodies to Alpha-Synuclein. Hari Shanker Sharma¹, José V Lafuente², Dafin F Mureseanu³, Rudy J Castellani⁴, Mark A Smith⁵, Ala Nozari⁶, Ranjana Patnaik⁷, Z Ryan Tian⁸, Asya Ozkizilcik⁹, Stephen D Skaper¹⁰, Herbert Mössler¹¹, Aruna Sharma¹ ((1) International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain; (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; a“RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania; (4) University of Maryland, Dept. of Pathology, Baltimore, MD, USA; (5) Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA; (6) Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA; (7) School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India; (8) Dept. Chemistry & Biochemistry &; (9) Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA; (10) Department of Pharmacology and Anesthesiology, University of Padua, Faculty of Medicine, Padua, Italy; (11) Ever NeuroPharma, Oberburgau, Austria)

P104: The Effect Of Crenezumab on Betaamyloid Toxicity–Induced Synapse Loss, Neurofibrillary Tangles and Cell Death in Human Neurons in Vitro. Ben Chih, Reina A. Bassil, Shirley Ng, Maureen Beresini (Genentech, Inc., South San Francisco, CA, USA)

Theme: New therapies and clinical trials

P5: Therapeutic Monitoring and Prediction of the Effectiveness of Neurotrophic Therapy in Patients with Mild Cognitive Impairment of the Amnestic Type. S.I. Gavrilova¹, O.M. Volpina², I.V. Kolykhalov¹, N.D. Selezneva¹, Y.B. Fedorovа¹, D.O. Karaev², A.V. Kamynina2 ((1) Mental Health Research Center, Moscow; (2) Institute of bioorganic chemistry M.M.Shemyakin and Y.A.Ovchinnikov Russian Academy of Sciences, Moscow)

P11: 11Β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Pharmacological Mechanism of Potential Therapeutic Uses-A Systematic Review. Sarah Gregory¹, John W. Ketelbey², Tamara Miller², Vincent S Ruffles², Craig W. Ritchie¹ ((1) University of Edinburgh, Edinburgh, UK; (2) Actinogen Medical Ltd, Sydney, New South Wales, Australia)

P20: Suvn-502 -Baseline Characteristics Of Phase 2A Study in Moderate Alzheimer's Disease -First-In-Class Triple Combination of Suvn-502+Donepezil+Memantine -A Promising New Approach for the Symptomatic Treatment of Alzheimers Disease. Ramakrishna Nirogi, Jyothsna Ravula, Satish Jetta, Koteshwara Mudigonda, Vinod Kumar Goyal, Santosh Kumar Pandey, Gopinadh Bhyrapuneni, Renny Abraham, Vijay Benade, Pradeep Jayarajan, Anil Shinde, John Ieni, Venkat Jasti (Discovery Research, Suven Life Sciences Ltd, Hyderabad, India)

P23: Efficacy and Safety of Trigriluzole (Bhv-4157) in Patients with Mild to Moderate Alzheimer'S Dementia: T2 Protect Ad Phase 2 Study Design. Irfan A. Qureshi¹, Karen Messer², Kirsten Erickson², Robert M. Berman¹, Carolyn Revta², Tilman Oltersdorf², Branko Huisa², Diane Jacobs², David Salmon², Doug Galasko², Thomas O. Obisesan³, Neelum Aggarwal⁴, Jacobo Mintzer⁵, Judith Heidebrink⁶, Amanda Smith⁷, Miranda N. Reed⁸, Holly C. Hunsberger⁸, Lia Donahue¹, Kimberly Gentile¹, David A. Stock¹, Vladimir Coric¹, Howard Feldman² ((1) Biohaven Pharmaceuticals, Inc., New Haven, CT, USA; (2) Alzheimer's Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA; (3) Howard University, Washington, DC USA; (4) Rush University Medical Center, Chicago, IL, USA; (5) Roper St. Francis Hospital, Charleston, SC, USA; (6) University of Michigan, Ann Arbor, MI, USA; (7) University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA; (8) Auburn University, Auburn, AL, USA)

P56: Gamma-Secretase Modulation Has Multiple Anti-Amyloidogenic Effects In Vivo. Bengt Winblad ^4,6, Gunnar Nordvall^1,2,3,4, Ping Yan⁵, Johan Lundkvist^1,2,3,4, Johan Sandin^1,2,3,4, Henrik Biverstål⁴, Henrik Zetterberg⁷, Rebecka Klintenberg³, Mats Ferm³, John R Cirrito⁵, Jin-Moo Lee⁵ ((1) AlzeCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden; (2) AlzeCure Foundation, Preclinical Research, Huddinge, Sweden; (3) AstraZeneca R&D, CNS & Pain iMed, Södertälje, Sweden; (4) Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden; (5) Washington University School of Medicine, Dept of Neurology, St Louis, USA; (6) Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden; (7) Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden)

P60: Discovery of Novel Molecular Chaperone Modulators for the Treatment of Tau Pathogenesis In Alzheimer'S Disease. Rajnish Kumar¹, Pavel Pavlov¹, Bengt Winblad^1,2 ((1) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden; (2) Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden)

P79: Cognixtra Preventive Treatment Affords Neuroprotection Against Amyloid Beta 25–35 Peptide-Induced Toxicity In Mice. Francois J. Roman¹, Johann Meunier¹, Laura Ceolin¹, Jean-Marie Butterlin², Guillaume Blivet³, Jacques Touchon⁴ ((1) Amylgen, Montferrier sur Lez -France; (2) Health Optimization Devices B.V. -Maastricht, Netherlands, www.cognixtra.com; (3) Montpellier -France; (4) INSERM U1061 & Montpellier University, Montpellier -France)

P84: Clinical Development of Axs-05 (Dextromethorphan/Bupropion) for Agitation Associated with Alzheimer'S Disease. Herriot Tabuteau, Amanda Jones, Cedric O'Gorman (Axsome Therapeutics Inc., USA)

P85: Pharmacokinetics and Safety Profile of Intravenous Administration of Allopregnanolone in Patients With Early Alzheimer'S Disease. Gerson D. Hernandez¹, Naoko Kono², Claudia M. Lopez¹, Ron Irwin³, Kathleen Rodgers¹, Jimmy Wu⁴, Rosario Mollo⁴, Sonia Pawluczyk⁵, Meng Law⁶, Wendy Mack², Lon Schneider⁵, Roberta D. Brinton¹ ((1) Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA; (2) Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; (3) School of Pharmacy, University of Southern California, Los Angeles, CA, USA; (4) TOMO Pharmacometrics, LLC, San Mateo, USA; (5) Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; (6) Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA)

P105: Sm07883, a Novel Dyrk1A Inhibitor, Reduced Tau Pathology – Discovery and Preclinical Development of a Potential Therapeutic for Alzheimer'S Disease. Benoît Melchior, Carolyn Lai, Karen Duong-Polk, Amanda Tjitro, Lauren Pitzer, Joshua Stewart, Luis Dellamary, Scott Anderson, Brian Hofilena, Chiao-Wen Chen, Charlene Barroga, Gopi Mittapalli, Sunil KC, Philippe Marchand, Yusuf Yazici (Samumed, LLC, San Diego, USA)

P106: Apabetalone, a Bet Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia and Vascular Endothelial Cells That Contribute to Neurodegenerative Disease. Ewelina Kulikowski¹, Emily Daze¹, Sylwia Wasiak¹, Dean Gilham¹, Laura M. Tsujikawa¹, Brooke Rakai¹, Stephanie C. Stotz¹, Christopher Halliday¹, Ravi Jahagirdar¹, Norman C. W. Wong¹, Michael Sweeney², Jan O. Johansson² ((1) Resverlogix Corp, Calgary, AB, Canada; (2) Resverlogix Inc, San Francisco, CA, USA)

P107: Clinico-Radiological Recovery of Arialike Events in Corticosteroid-Treated Caa-Ri Patients: Implications for the Management Of Aria Side Effects Of Anti-Amyloid Immunotherapy. Fabrizio Piazza^1,2,3,4, on behalf of The iCAβ International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia*, Jacopo C. DiFrancesco^1,2,3, Marialuisa Zedde^1,5, Federica Angiulli^1,3, Rosario Pascarella⁵, Roberto Marconi⁶, Francesco Perini⁷, Alberto Villarejo-Galende⁸, Mario Cirillo⁹, Berardino Orlandi¹⁰, Ihara Masafumi¹¹, Mehdi Touat¹², Hagiwara Yuta¹⁶, Juan F. Vázquez-Costa¹⁴, Massimo Caulo¹⁵, Shima Atsushi¹⁶, Alessia Giossi¹⁷, Ricardo Nitrini¹⁸, Massimo Musicco^2,4 *Main Network Collaborators ((1) The inflammatory cerebral amyloid angiopathy and Alzheimer's disease βiomarkers (iCAβ) International Network, University of Milano Bicocca, Monza, Italy; (2) The CAA Study Group of the Italian Society of Neurology for dementia (SINdem), Italy; (3) University of Milano Bicocca, Monza, Italy; (4) National Research Council, Segrate, Italy; (5) Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy; (6) Department of Neuroscience, Ospedale Misericordia, Grosseto, Italy; (7) St. Bortolo Hospital, Vicenza, Italy; (8) Hospital 12 de Octubre. CIBERNED, Madrid, Spain; (9) Università della Campania «L. Vanvitelli», Seconda Università degli Studi di Napoli, Italy; (10) S.S. Filippo and Nicola Hospital in Avezzano, L'Aquila, Italy; (11) National Cerebral and Cardiovascular Center, Osaka, Japan; (12) Dana-Farber Brigham and Women's Hospital, Boston, Massachusetts, USA; Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, Paris, France; (13) St. Marianna University School of Medicine, Japan; (14) Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain; (15) University «G. d'Annunzio», Chieti, Italy; (16) Kyoto University Graduate School of Medicine. Kyoto, Japan; (17) O.U. of Neurology, ASST Cremona, Italy; (18) University of São Paulo School of Medicine, São Paulo, Brazil)

P108: Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly Corplextm Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept. Bobby Singh (Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA)

LATE BREAKING NEWS

Theme: Clinical trials: Methodology

Theme: Clinical trials: Results

LBP13: Cognitive And Mobility Training as Preventive Measures in Cognitively Healthy Patients And Patients With Mci. Carine Federspiel^1,2, Elisabeth Bourkel¹, Jean-Paul Steinmetz^1,2 ((1) Centre for memory and mobility, ZithaAktiv, Luxembourg; (2) ZithaSenior, Research&Development, Luxembourg)

LBP14: Evidence Of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer'S Disease: Consistency of Multiple Evaluation Analyses. Daniel Alkon¹, LJ Wei², Richard Thompson³ ((1) Neurotope,Inc; (2) Harvard University (3) Johns Hopkins University)

LBP15: Enterovirus Might Be Involved in Alzheimer'S Disease -Results from a Phase Iia Trial Evaluating Apovir, an Antiviral Drug Combination. Lars-Olof Wahlund¹, Lars Lindqvist², Mikael Åström³, Jacob Westman⁴, Roger Bullock⁵, Suzanne Hendrix⁶, Nina Lindblom⁴ ((1) Karolinska University Hospital, Huddinge, Sweden; (2) Karolinska University Hospital, Huddinge, Sweden ;(3) StatCons, Limhamn, Sweden; (4) Apodemus AB, Solna, Sweden; (5) Roger Bullock Consulting Ltd, Swindon, UK; (6) Pentara Corporation, Salt Lake City, -USA)

LBP16: A RANDOMIZED, PLACEBO CONTROLLED, REPEAT DOSE PHASE 1 STUDY OF COR388 IN OLDER HEALTHY VOLUNTEERS AND PATIENTS WITH ALZHEIMER'S DISEASE. Samer Kaba¹, Casey Lynch¹, Mark Ryder², Ira Goodman⁴, Steve Thien⁴, Steve Dominy¹ ((1) Cortexyme, S. San Francisco, CA; (2) UCSF, San Francisco, CA; (3) Bioclinica, Orlando, FL; (4) Pacific Research Network, San Diego, CA)

LBP17: Souvenaid in Cognitive Deterioration. Our Experience After 5 Years of Treatment And Follow-Up. Miquel Aguilar, Paquita Soler. Nurse (Àptima Mutua Terrassa. Catalunya, Spain)

LBP18: Is Rage The Missing Link Between Diabetes and Dementia? Results From A Subgroup Analysis of the Steadfast Trial. Carmen Valcarce¹, Imogene Dunn¹, Tom Soeder²,Aaron Burstein¹ ((1) vTv Therapeutics LLC, High Point, NC, USA; (2) CATO Research Ltd., Durham, NC, USA)

LBP19: Aducanumab 48-Month Analyses From Prime, a Phase 1B Study in Patients with Early Alzheimer'S Disease. Philipp von Rosenstiel¹, Samantha Budd Haeberlein¹, Carmen Castrillo-Viguera¹, Tianle Chen¹, John O'Gorman¹, Raj Rajagovindan¹, Dakshaben Patel², Guanfang Wang³, Spyros Chalkias¹, LeAnne Skordos¹, Claudia Prada¹, Christoph Hock⁴, Roger M Nitsch⁴, Alfred Sandrock¹ ((1) Biogen, Cambridge, MA, USA; (2) Biogen, Maidenhead, UK; (3) Cytel, Cambridge, MA, USA; (4) Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland)

LBP20: Baseline Data from the Api Autosomal Dominant Alzheimer'S Disease Colombia Trial. Pierre N. Tariot¹, Francisco Lopera², Kaycee M. Sink³, Nan Hu³, Heather Guthrie³, Jillian Smith⁴, William Cho³, Jessica B. Langbaum¹, Ronald G. Thomas⁵, Kewei Chen¹, Yi Su¹, Dhruman Goradia¹, Pradeep Thiyyagura¹, Paul S VanGilder¹, Ji Luo¹, Valentina Ghisays¹, Wendy Lee¹, Michael H. Malek-Ahmadi¹, Hillary D. Protas¹, Yinghua Chen¹, Carole Ho³, Shehnaaz Suliman³, Sergio Alvarez⁵, Yakeel T. Quiroz⁶, Robert Paul⁷, Silvia Rios Romenets², Eric M. Reiman¹, and the API ADAD Colombia Trial Group. ((1) Banner Alzheimer's Institute, Phoenix, AZ, USA; (2) Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, CO, (3) Genentech Inc., South San Francisco, CA, USA; (4) Roche Products Ltd, Welwyn Garden City, UK; (5) University of California, San Diego, CA, USA; (6) Hospital Pablo Tobon Uribe, Medellin, CO; (7) Harvard Medical School and Massachusetts General Hospital, Boston MA, USA)

Theme: Clinical trials: Imaging

LBP21: Prediction of Treatment Response to Donepezil Using Automated Hippocampal Subfields Volumes Segmentation in Patients With Mild Alzheimer's Disease. Sheng-Min Wang¹, Yoo Hyun Um², Chang-Uk Lee³, Hyun Kook Lim³ ((1) Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul -Republic of Korea; (2) St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon -Republic of Korea; (3) Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul -Republic of Korea)

LBP22: Role of Confluent White Matter Lesions in the Progression to Alzheimer'S Dementia in An Asian Clinic Cohort. Nagaendran Kandiah (National Neuroscience Institute,Singapore)

LBP23: Apoe4/4 Early to Mild Ad Subjects Show High Rates Of Hippocampal Atrophy and Cognitive Decline In Adni-1 and Tramiprosate Datasets. Susan Abushakra¹, Luc Bracoud², Joël Schaerer², Aidan Power¹, John Hey¹, David Scott³, Joyce Suhy³, Martin Tolar1 & the Alzheimer Disease Neuroimaging Initiative (ADNI) ((1) Alzheon Inc., Framingham, MA, USA; (2) Bioclinica, Lyon France (3) Bioclinica, Newark CA, USA)

LBP24: Preliminary Characterization of 18Fro948 Pet Imaging Among Cognitively Unimpaired and Patients with Mci or Dementia In The Biofinder2 Study. Gregory Klein¹, Ruben Smith², Sebastian Palmqvist², Niklas Mattsson², Danielle van Westen², Olof Strandberg², Jonas Jögi², Tomas Ohlsson², Edilio Borroni¹, Preciosa Coloma¹, Erik Stomrud², Oskar Hansson² ((1) Roche Pharma Research and Early Development, Basel, Switzerland; (2) Clinical Memory Research Unit, Lund University, Sweden)

Theme: Clinical trials: Biomarkers including plasma

LBP25: Discovery Of An Endogenous Metabolite of Tramiprosate and Its Prodrug Alz-801 That Inhibits Beta Amyloid Oligomer Formation in Human Brain. John A. Hey¹, Petr Kocis¹, Jakub Hort^2,3, Susan Abushakra¹, Aidan Power¹, Martin Vyhnálek^2,3, Jeremy Y. Yu1, Martin Tolar¹ ((1) Alzheon, Inc., Framingham, MA, USA; (2) International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic; (3) Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic)

LBP26: Novel Use of Aptamer Libraries for Prediction of Amyloid Status From Blood Serum. Gregory Penner¹, Soizic Lecocq¹, Anaëlle Chopin¹, Simone Lista^2,3,4,5, Andrea Vergallo^2,3,4,5, Enrica Cavedo^2,3,4,5, Francois-Xavier Lejeune⁴, Harald Hampel^2,3,4,5 the INSIGHTpreAD study group and the Alzheimer Precision Medicine Initiative (APMI) ((1) NeoNeuro SAS, Villejuif Bio Park, Villejuif, France; (2) AXA Research Fund & Sorbonne University Chair, Paris, France; (3) Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Paris, France; (4) Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France; (5) Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France)

LBP27: Novel Cerebrospinal Fluid Synaptic Markers in Alzheimer'S Disease for Potential Use in Clinical Trials. Alberto Lleó^1,2, Raúl Núñez-Llaves^2,3, Daniel Alcolea^1,2, Martí Colom-Cadena^2,3, Laia Muñoz^2,3, Marta Querol-Vilaseca^2,3, Jordi Pegueroles^2,3, Lorena Rami⁴, Albert Lladó⁴, José L. Molinuevo⁴, Mikel Tainta⁵, Jordi Clarimón^2,3, Tara Spires-Jones⁶, Rafael Blesa^1,2, Juan Fortea^1,2, Pablo Martínez-Lage⁵, Raquel Sánchez-Valle⁴, Àlex Bayés^7,8, Olivia Belbin^2,3 ((1) Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; (2) Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; (3) Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; (4) Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; (5) Department of Neurology, Center for Research and Advanced Therapies, CITAAlzheimer Foundation, San Sebastian, Spain; (6) Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh; (7) Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; (8) Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain)

LBP28: Diminished Platelet-Derived Hsa-Mir-150-5P Expression as Biomarker for Dementia with Lewy Bodies Versus Alzheimer'S Disease. Katrin Beyer¹, Ana Gámez-Valero^1,2, Jaume Campdelacreu³, Dolores Vilas⁴, Lourdes Ispierto⁴, Jordi Gascón-Bayarri³, Ramón Reñé³, Ramiro Álvarez⁴, Maria P Armengol⁵, Francesc E. Borràs² ((1) Department of Pathology, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain; (2) REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Spain; (3) Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; (4) Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; (5) Genomic and Microscopy facilities, Institut Investigació Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona (Barcelona), Spain)

LBP29: Development of Polygenic Risk Scores (Prs) for Common Neuropathology. Julie Collens, Mike Nalls, Marcel van der Brug (Vivid Genomics, Inc. San Diego, CA, USA)

LBP30: The Italian Inter-Societal Consensual Algorithm for the Biomarker-Based Diagnosis of Mild Cognitive Impairment. Marina Boccardi^1,2, Valentina Nicolosi¹, Cristina Festari^1,3, Angelo Bianchetti^4,5, Stefano Cappa^1,6,7, Davide Chiasserini^8,9, Andrea Falini^10-13, Ugo Paolo Guerra^14,15, Flavio Nobili^15-17, Alessandro Padovani^7,18, Giulia Maria Sancesario^9,19, Francesca Benedetta Pizzini^13,20, Alberto Beltramello^13,21, Marcello Ciaccio^9,22, Orazio Schillaci^15,23, Marco Trabucchi^5,24, Fabrizio Tagliavini²⁵, Giovanni Battista Frisoni^1,2,26 ((1) Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (2) LANVIE -Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland; (3) University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy; (4) Medicine and Rehabilitation Department, Istituto Clinico S. Anna, Brescia, Italy; (5) Italian Psychogeriatric Association (AIP), Brescia, Italy; (6) NEtS Center, Scuola Universitaria Superiore IUSS, Pavia, Italy; (7) Italian Society of Neurology -Association for the Study of the Dementias (SINdem), Italy; (8) Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy; (9) Italian Society of Clinical Biochemistry and Clinical Molecular Biology -Laboratory Medicine (SIBioC), Italy; (10) Division of Neuroscience, IRCCS San Raffaele, Milan, Italy; (11) Vita-Salute San Raffaele Università, Milan, Italy; (12) Neuroradiology Unit, IRCCS San Raffaele hospital, Milan, Italy; (13) Italian Association of Neuroradiology (AINR), Italy; (14) Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy; (15) Italian Association of Nuclear Medicine (AIMN), Italy; (16) Clinical Neurology, Dept of Neuroscience (DiNOGMI), University of Genoa, Italy; (17) IRCCS Ospedale Policlinico San Martino, Genova, Italy; (18) Neurology Clinic, Department of Clinical and Experimental Sciences, Brescia, Italy; (19) Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, Rome, Italy; (20) Department of Neuroradiology, General Hospital, Verona, Italy; (21) Dipartimento di Diagnostica per Immagini, IRCCS Ospedale Classificato «Sacro Cuore -Don Calabria», Negrar, Verona; (22) Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy; (23) Department of Biomedicine and Prevention, University Tor Vergata, Rome , Italy; (24) Tor Vergata, Rome University, Rome, Italy; (25) Division of Neurology V/Neuropathology, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy; (26) Memory Clinic, University Hospital, Geneva – Switzerland)

LBP31: Secondary Structure of Aβ As Blood Biomarker. Klaus Gerwert (Department of Biophysics Ruhr University Bochum, Germany)

LBP32: Bdnf As A Biomarker for the Effects of P38 Mapkα Inhibition on Il-1Β-Induced Impairment of Hippocampal Synaptic Plasticity. John Alam1, Charlotte Teunissen², Niels Prins^3,4, Hui-May Chu⁵, Philip Scheltens³ ((1) EIP Pharma Inc, Cambridge MA, USA; (2) Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL; (3) Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL; (4) Brain Research Center, Amsterdam, NL; (5) Anoixis Corporation, Framingham MA, USA)

LBP33: Impact of Pre-Analytical Sample Handling on Elecsys Aβ40, Aβ42 And Ttau Immunoassays in Plasma. Malgorzata Rozga¹, Tobias Bittner², Richard Batrla-Utermann³, Johann Karl¹ ((1) Roche Diagnostics GmbH, Penzberg, Germany; (2) Genentech, A member of the Roche Group, Basel, Switzerland; (3) Roche Diagnostics International AG, Rotkreuz, Switzerland)

LBP34: Agreement Between Visual Amyloid Pet and Cerebrospinal Fluid Aβ1–42, Aβ1–40, T-Tau And P-Tau on The Lumipulse G Fully Automated Platform. Alberto Lleó^1,2, Jordi Pegueroles^1,2, Laia Muñoz^1,2, Valle Camacho³, Diego López-Mora³, Alejandro Fernández-León³, Nathalie Le Bastard⁴, Els Huyck⁴, Alicia Nadal⁵, Verónica Olmedo⁵, Víctor Montal^1,2, Eduard Vilaplana^1,2, Rafael Blesa^1,2, Juan Fortea^1,2, Daniel Alcolea^1,2 ((1) Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau -Biomedical Research Institute Sant Pau -Universitat Autònoma de Barcelona, Barcelona, Spain; (2) Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Spain; (3) Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau -Biomedical Research Institute Sant Pau -Universitat Autònoma de Barcelona, Barcelona, Spain; (4) Fujirebio Europe NV, Gent, Belgium; (5) Fujirebio Iberia, SLU, Barcelona, Spain)

LBP35: Does Non-Disclosure of Apoe Genotyping Prevent Subject Interest or Participation in Clinical Trials? Sean Stanton¹, Vishnukartik Nitta², Jessica Branning² ((1) LifeCore Solutions, Winter Park, USA; (2) ClinCloud, LLC, Orlando -USA)

LBP36: Measurement Of Pathological Amyloid in a Patient Cohort in Routine Clinical Assessment: Comparison of Visual [18F] Flutemetamol Pet Read And Csfs Measures. Nenad Bogdanovic¹, Enrico Fantoni², Gill Farrar² ((1) Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway; (2) GE Healthcare Life Sciences. Amersham, UK and Boston, USA)

LBP37: Kinetic Measurement of Newly Generated Bace1-Cleaved App in the Human Central Nervous System in Alzheimer's Disease: A Pilot Study. Robert J. Vassar¹, Randall J. Bateman², Bruce W. Patterson³, Justyna A. Dobrowolska Zakaria¹ ((1) Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; (2) Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA; (3) Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA)

LBP38: Reliability of a Rapid Apoe Assay for Alzheimer'S Risk Assessment and Clinical Trial Screening. Athene Lee^1,2, William Menard², Gina Tonini², Louisa Thompson^1,2 Jessica Alber^1,2, Stephen Salloway^1,2 ((1) Warren Alpert Medical School of Brown University, Providence, RI, USA; (2) Butler Hospital, Providence, RI, USA)

LBP39: Cerebrospinal Fluid Profiling of Multiple Pathophysiological Pathways in Alzheimer'S Disease. Steven Arnold¹, Bianca A. Trombetta², Becky C. Carlyle² ((1) Massachusetts General Hospital and Harvard Medical School; (2) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA)

LBP40: Interim Biomarker Analyses Of Phase Ii Study Data on Safety And Efficacy of Gm Csf in Mild-To-Moderate Alzheimer'S Disease. Timothy D. Boyd^1,2, Jonathan Woodcock^1,3, Stefan Sillau^1,3, Vanesa Adame^1,2, Thomas Borges^1,4, Ashesh Thaker^1,4, Brianne Bettcher^1,5, Joseph Daniels^1,3, Kate Heffernan¹, Huntington Potter^1,2,3 ((1) Rocky Mountain Alzheimer's Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; (2) Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; (3) Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA; (4) Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA; (5) Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA)

Theme: Clinical trials: Cognitive and functional endpoints

L B P 4 1 : E F F E C T S O F 2 -Y Ear Walnut Supplementation On Cognitive Decline In Healthy Elders: The Walnuts and Healthy Aging (Waha) Study. Nina Coll-Padrós¹, Aleix Sala-Vila^2,3, Cinta Valls-Pedret², Mercè Serra-Mir^2,3, Montserrat Cofán^2,3, Irene Roth², Tania Freitas-Simoes², Mónica Doménech², Lídia Vaqué-Alcázar⁴, David Bartrés-Faz⁴, Sujatha Rajaram⁵, Joan Sabaté⁵, Emilio Ros^2,3 ((1) Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; (2) Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona, Spain; (3) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain; (4) Institut de Neurociències i Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona Spain; (5) School of Public Health, Loma Linda University, Loma Linda, CA, U.S.A.)

LBP42: Adcoms: A Post-Hoc Analysis Using Data from the Lipididiet Trial in Prodromal Alzheimer'S Disease. Suzanne B. Hendrix¹, Hilkka Soininen^2,3, Pieter Jelle Visser^4,5, Alina Solomon^2,6,7, Miia Kivipelto^2,6,7, Tobias Hartmann^8,9 on behalf of the LipiDiDiet clinical study group ((1) Pentara Corporation, Salt Lake City, UT, USA; (2) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; (3) Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland; (4) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands; (5) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; (6) Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden; (7) Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, 14152 Huddinge, Sweden; (8) Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany; (9) Department of Experimental Neurology, Saarland University, Homburg, Germany)

LBP43: Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients With Alzheimer's Disease Dementia: A Phase I Clinical Trial. Hee Jin Kim^1,2, Kyung Rae Cho^2,3, Hyemin Jang^1,2, Jung Il Lee^2,3, Seongbeom Park^1,2, Soo Jin Choi⁴, Sung Tae Kim⁵, Seung Hwan Moon⁶, Kyung-Han Lee⁶, Sang Won Seo^1,2,7, Duk L. Na^1,2,8) ((1) Departments of Neurology; (3) Neurosurgery; (5) Radiology; (6) Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; (2) Neuroscience Center, Samsung Medical Center, Seoul, Korea; (4) Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul, Korea; (7) Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea; (8) Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea)

LBP44: Exploratory Analysis of Results from the Nilvad Trial Suggest Benefit In Very Mild Ad Subjects. Michael Mullan^1,2, Laila Abdullah², Heather Langlois², Fiona Crawford^1,2, Anders Wallin³, Suzanne Hendrix⁴, Kaj Blennow⁵, Brian Lawlor⁶ The NILVAD consortium ((1) Archer Pharmaceuticals, Sarasota, FL, USA; (2) Roskamp Institute, Sarasota, FL, USA; (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden; (4) Pentara Corporation, Salt Lake City, UT, USA; (5) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden; (6) Trinity College Dublin, Dublin, Ireland)

LBP45: Can Digital Footprints Capture Clinically Relevant Gait Endpoints in Nonclinically Setting: A Proof of Concept? Marie Mc Carthy¹, Crystal Gon² ((1) ICON PLC, Dublin, Ireland; (2) Trinity College Dublin, Ireland)

LBP46: Using the Power of Dementias Platform Uk (Dpuk) Cohorts to Investigate The Longitudinal Effects of Childhood Adversity on Adult Cognition and Health Outcomes: Implications for Cognitive Change And Dementia Outcomes. Sarah Bauermeister, John Gallacher (University of Oxford, Department of Psychiatry, Oxford, UK)

Theme: Cognitive assessment and clinical trials

LBP47: Strategic Memory Alzheimers Rehabilitation Training (Smart) Memory Program for Amnestic Mild Cognitive Impairment (Amci): Reporting The Results of a Randomized Clinical Trial. John W. DenBoer (SMART Brain Aging, Inc.)

LBP48: Memory Errors of Commission Rather Than Errors of Omission Discern Aging and Early Alzheimer'S Disease. Matthias W. Riepe, Claudia Lanza, Karolina Sejunaite (Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany)

LBP49: Standard Cognitive Assessment in the Era of Biomarkers and Disease-Modifiers. Marina Boccardi^1,2, Stefano Cappa², Bruno Dubois³, Jean Georges⁴, Matthias Kliegel⁵, Bengt Winblad⁶, David Salmon⁷, Giovanni Frisoni^1,2, Andreas Monsch⁸ for the Task Force for Harmonizing Neuropsychological Assessment for Dementing Neurodegenerative Disorders ((1) LANVIE -Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland; (2) IRCCS S.Giovanni di Dio – Fatebenefratelli, Brescia, Italy; (3) Dementia Research Center, Hôpital Pitié-Salpêtrière, Paris, France; (4) Alzheimer Europe; (5) Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland; (6) Karolinska University Hospital, Stockholm, Sweden; (7) Department of Neurosciences, University of California San Diego School of Medicine, United States; (8) University of Basel, Basel, Switzerland)

LBP50: Lanabecestat: Rater Performance and Error Characteristics of Efficacy Assessments in the Daybreak-Alz Study. Alette M. Wessels¹, Jordan Mark Barbone², Danielle T. DiGregorio², David S. Miller², Jamie A. Mullen³, John R. Sims¹ ((1) Eli Lilly and Company, Indianapolis, IN, USA; (2) Bracket, Wayne, PA, USA (3) AstraZeneca Pharmaceuticals, Cambridge, MA, USA)

LBP51: Ipsc Model of Chrfam7A Effect on A7 Nicotinic Acetylcholine Receptor Function May Explain The Translational Gap in Drug Development. Ivanna Ihnatovych¹, Tapan Nayak¹, Aya Ouf¹, Norbert Sule², Barbara Birkaya¹, Lee Chaves¹, Anthony Auerbach1 ((1) SUNY at Buffalo; (2) Roswell Park Cancer Institute)

LBP52: Effects of Age and Csf Measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways. David Berron^1,2,3, Arturo Cardenas-Blanco⁴, Daniel Bittner², Coraline D. Metzger⁵, Annika Spottke^6,7, Michael Heneka^7,8, Klaus Fließbach^9,10, Anja Schneider^7,8, Stefan J. Teipel^11,12, Michael Wagner^7,13, Oliver Speck¹⁴, Frank Jessen^7,15, Emrah Düze^l4,5 the DELCODE study group ((1) Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden; (2) University Hospital Magdeburg, Magdeburg, Germany; (3) German Center for Neurodegenerative Diseases, Magdeburg, Germany; (4) German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany; (5) Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany; (6) Department of Neurology, University Hospital of Bonn, Bonn, Germany; (7) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; (8) Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany; (9) DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany; (10) Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; (11) Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany; (12) German Center for Neurodegenerative Diseases, Rostock, Germany; (13) Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital, Bonn, Germany; (14) Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany; (15) Department of Psychiatry, University Hospital Cologne, Cologne, Germany)

Theme: Behavioral disorders and clinical trials

LBP53: Prevalence of Obstructive Sleep Apnea in Alzheimer'S Disease Patients. Anna Carnes¹, Carme Jorge¹, Benítez^2,3, Faride Dakterzada¹, Olga Minguez², Raquel Huerto¹, Montse Pujol², Anna Gaeta², Alfonso Arias¹, Aurora Gibert¹, Manuel Sanchez de la Torres^2,3, Ferran Barbé^2,3, Gerard Piñol-Ripoll¹ ((1) Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain; (2) Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain; (3) Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain)

Theme: Clinical trials: Epidemiology and clinical trials

LBP54: Psychometric Methodologies to Increase Scale-Reliability in Dementia-Focused Epidemiology: Outcomes from the European Prevention Of Alzheimer'S Disease Study and UK Biobank. Sarah Bauermeister, John Gallacher (University of Oxford, Department of Psychiatry, Oxford, UK)

LBP55: Stopbang And Berlin Questionnaire as Screening Tools to Identify Obstructive Sleep Apnea in Alzheimer'S Disease. Anna Carnes¹, Benítez^2,3, Faride Dakterzada¹, Olga Minguez², Raquel Huerto¹, Montse Pujol², Anna Gaeta², Alfonso Arias¹, MD, Aurora Gibert¹, Manuel Sanchez de la Torres^2,3, Ferran Barbé^2,3, Gerard Piñol-Ripoll1 ((1) Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain; (2) Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain; (3) Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain)

LBP56: Exposure to Benzodiazepines and Development of Alzheimer'S Disease: A Cohort Study in a Health Region of Catalonia Between 2002 and 2015. Carnes A¹, Torres-Bondia FI¹, de Batlle J², Piñol-Ripoll G¹ ((1) Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida, Spain; (2) Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain)

Theme: Animal model and clinical trials

LBP57: Adult Conditional Bace1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus. Robert Vassar (Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA)

LBP58: Disease Modifying Therapy By Targeting Generic Protein Secondary Structure of Pathological Oligomers at Any Stages of Alzheimer'S Disease Models. Fernando Goni, Krystal Herline, Mitchell Marta-Ariza, Frances Prelli, Thomas Wisniewski (New York University School of Medicine, New York, -USA)

Theme: New therapies and clinical trials

LBP59: Triple Therapy With Suvn-502, a 5-Ht6 Antagonist, Donepezil And Memantine in Moderate Alzheimer'S Disease: Baseline Patient Characteristics in Phase-2A Study. Alireza Atri^1,2, Jeffrey L. Cummings³, John Ieni⁴, Venkat Jasti⁴, Ramakrishna Nirogi⁴ ((1) Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA; (2) Center for Brain/Mind medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; (3) Cleveland Clinic, Las Vegas, NV, USA; (4) Discovery Research, Suven Life Sciences, Hyderabad, India)

LBP60: Clinical Polysomnography Trial of Suvorexant for Treating Insomnia in Alzheimer'S Disease: Trial Design and Baseline Characteristics of Participants. W.J. Herring¹, P. Ceesay¹, E. Snyder¹, D. Bliwise², K. Budd¹, J. Hutzelmann¹, J. Stevens¹, D. Michelson¹ ((1) Merck & Co. Inc., Kenilworth, NJ, USA; (2) Emory University School of Medicine, Atlanta, GA, USA)

LB61: Neuroprotective Effect of a New Photobiomodulation Technique Against Amyloid Aβ25–35 Peptide Induced Toxicity in Mice Might Support a Novel Hypothesis For Therapeutic Approach of Alzheimer'S Disease. Guillaume J. Blivet¹, Laura Auboyer¹, Johann Meunier², François J. Roman², Jacques Touchon^3,4 ((1) REGEnLIFE SAS, Montpellier, France; (2) Amylgen SAS, Montferrier-sur-Lez, France; (3) INSERM U1061, Montpellier, France, 4Neurology Department, University of Montpellier, France)

LBP6 2 : Interest Of Regenli F E Rgn5 3 0 Photobiomodulation Medical Device for the Treatment of Alzheimer's Disease: A Doubleblind, Randomized Sham-Controlled Trial to Evaluate The Safety and Efficacy. Audrey Gabelle^1,2, Thibault Mura^2,3, Karim Bennys^1,2, Sophie Navucet^1,2, Martine Flores^1,2, Laura Auboyer⁴, Guillaume J. Blivet⁴, Jacques Touchon^1,2 ((1) Memory Research and Resources Center of Montpellier, Department of Neurology, Montpellier University Hospital, France; (2) MUSE University, Inserm U1061, Montpellier, France; (3) Department of Epidemiologic and Clinical Research, La Colombière Hospital, Montpellier, France; (4) REGEnLIFE SAS, Montpellier, France

Export

Vol 5 - N° S1

P. 46-196 - octobre 2018 Retour au numéro

Article précédent

Symposia

| Article suivant

Posters

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Posters - 21/11/24

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL